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ABSTRACT
RAPID, SITE-SPECIFIC LABELING OF ‘OFF-THE-SHELF’ AND NATIVE SERUM
AUTOANTIBODIES WITH T CELL-REDIRECTING DOMAINS
Fabiana Zappala
Dr. Andrew Tsourkas
Generating new bispecific antibodies typically requires extensive engineering and
cloning. New technologies such as made-to-order genes, advanced expression systems,
and high efficiency cloning have simplified and accelerated this process. However, the
timeline to create new bispecific antibodies is in the order of months, the resulting yield
can be low, and adequate functionality is not guaranteed.
Here, we developed a simple method to produce bispecific antibodies by sitespecifically and covalently attaching a T cell redirecting domain to any off-the-shelf,
human Immunoglobulin G (IgG). Our method excludes antibody engineering, cloning or
prior knowledge of the antibody sequence, and the bispecifics are created in two hours.
We demonstrated the applicability by assessing in vitro cytolysis of bispecific antibodies
made using three FDA-approved monoclonal antibodies.
We also show the ability to create personalized T cell redirecting autoantibodies
(TRAAbs) by labeling native antibodies isolated from tumor-bearing mice, including two
syngeneic murine models. TRAAbs were found to induce anti-tumor effects in vitro and
in vivo. TRAAbs were also found to preferentially bind tumor over healthy tissue,
highlighting a window for safe therapy. The use of autoantibodies to direct the tumor
targeting of bispecific antibodies represents a new paradigm in personalized medicine
iv

that eliminates the need to identify tumor biomarkers and can potentially overcome tumor
antigen loss, which commonly results from mono-targeted immunotherapies.
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CHAPTER 1: BACKGROUND

1.1 INTRODUCTION TO CANCER IMMUNOTHERAPY
Before the development of immunotherapies for cancer treatment, the standard of
care involved chemo- and/or radiotherapy. While these traditional therapies remain first
in line for many types of cancers, the limited therapeutic efficacy and generally severe
side effects have led to increasing interest in alternatives such as immunotherapy.
Generally, one main advantage provided by immunotherapies is the ability to treat tumors
in a more targeted manner, although this is now also possible with nanoparticles loaded
with chemotherapeutics and used in combination with radiotherapy. Tumor-targeted
immunotherapy increases efficacy and reduces side effects compared to untargeted
chemotherapy by limiting the location of its effects to the tumor. Additionally, cancer
treatment with immunotherapies provides a better window for long-term antitumor
effects, since theoretically the immune system can be trained to retain memory against
tumors. This is not possible without engaging the immune adaptive branch, as is the case
with chemo- and radiotherapy.
To date, the earliest and most thoroughly studied types of immunotherapies are
antibody-based. Monoclonal antibodies have become part of the treatment toolbox for
many types of diseases. Their wide applicability was made possible by decades of
research and development. Two key technologies that have enabled an increasingly
bigger body of therapeutic monoclonal antibodies entering the clinic are phage display
and hybridomas. Their success has led to further interest in this type of immunotherapy,
and today it has expanded to include various types of bispecific antibodies as well as
1

antibody-drug conjugates. There are two growing categories of technologies that are
further spurring the field of antibody-based cancer therapeutics. First, next-generation
sequencing is enabling the identification of new targets and druggable biological
pathways. Second, new conjugation methods are speeding up the creation of bispecific
and multi-specific therapeutics as well as antibody-drug conjugates. The following
background chapter will cover these topics in detail.
Besides antibody-based immunotherapies, alternative strategies covered in this
thesis include cell-based, gene delivery, and oncolytic viruses. Each of these categories
are characterized by different advantages and disadvantages as summarized in Table 1.1.
Subsections 1.3 through 1.5 will respectively describe these therapies in detail, including
their mechanisms of actions, examples that have been tested in the clinic and examples of
FDA-approved treatments if they exist already.

1.1.1 A case study: the history of lymphoma treatment with new immunotherapies
Currently, immunotherapies are available for treating a wide variety of cancers,
including bladder, colorectal, kidney, head and neck, leukemia, lymphoma, and
melanoma1. The history of lymphoma treatment is an interesting example of how
immunotherapies have impacted the standard of care in cancer. This example
encapsulates both the significant advances achieved with immunotherapy as well as the
future opportunities to continue improving patient outcomes. Currently, combined chemo
and immunotherapy using anti-CD20 monoclonal antibody rituximab is the first-line
standard of care for many lymphoma subtypes2,3. For aggressive lymphomas such as
2

diffuse large B cell (DLBCL), the most common type of Non-Hodgkin’s lymphoma in
the US, chemo-immunotherapy leads to complete response in around 75-80% of
patients2. In young patients, adding rituximab to chemotherapy increased the 3-year
event-free survival from 59% to 79% in a controlled randomized trial4.
However, patients who relapse or have refractory disease still face poor
prognosis. The prognosis for those who relapse within the first year of treatment is as low
as 23% 3-year progression-free survival with salvage therapy, which includes high dose
chemotherapy followed by autologous stem cell transplant (AHSCT) leading to a 63%
response rate. Patients who don’t respond to at least two types of treatment are now able
to receive cellular adoptive therapy using autologous T cells modified with chimeric
antigen receptors (CAR-T). CAR-T was first approved in 2017 for patients under 25 with
B-cell precursor acute lymphoblastic leukemia (ALL) whose disease is refractory to
treatment or who have relapsed after second-line therapy or beyond and for adult patients
with certain types of relapsed or refractory large B-cell lymphoma, including DLBCL,
primary mediastinal B-cell lymphoma (PMBCL), high-grade B-cell lymphoma, and
DLBCL arising from follicular lymphoma (FL). In one clinical trial lisocabtagene
maraleucel CAR-T, marketed as Breyanzi, resulted in an overall response rate of 73%,
with 54% complete response5. Despite its high response rate in otherwise untreatable
patients, CAR-T treatment also leads to serious adverse side effects in 46% of the
patients, including cytokine release syndrome (CRS), encephalopathy, sepsis and fatal
reactions in 4% of the patients in one trial. This example shows the significant impact
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that immunotherapies are having on patient outcomes as well as the room for
improvement left for scientists to investigate.
Before jumping into the specifics of each type of cancer immunotherapy
discussed in this thesis, a brief summary is provided in the following table.
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Table 1.1. Summary of Immunotherapies.

Category

Concept/mechanisms of action

Advantages

Disadvantages

5

Antibody-based
immunotherapies

Monoclonal antibodies:
1. Upregulate cell death pathways and/or
downregulate cell survival pathways
2. Target antibody-dependent cellular
cytotoxicity (ADCC) and complementdependent cytotoxicity (CDC).
3. “Release the breaks” of tumor
immunosuppression by disrupting PD1/PD-L1 interactions, for example
Bispecific antibodies:
4. Recruit cytotoxic immune cells such as T
and NK cells to target tumor cell death

• Research and
manufacturing
technologies are
somewhat well defined,
for monoclonal antibodies
at least
• Non-invasive

• Poor solid tumor
penetration
• Long infusion times
needed to reach
therapeutic dose
• Severe side effects
include CRS
• Need to identify valid
tumor antigens

Cellular
immunotherapies

• Autologous T cells are genetically
engineered to re-direct cellular immune
killing towards tumor cells
• T cells are engaged and activated once the
chimeric receptor binds its target

• Need to identify valid
tumor antigens
• Severe side effects (CRS,
encephalitis etc)
• Complex manufacturing

Cancer vaccines

• Gene based: identified tumor-specific
genes are delivered as DNA or mRNA
pieces in a vector (ex: lipid nanoparticles)
to induce long-term protection by
engaging the adaptive branch of the
immune system
• Peptide-based: similar to gene-based but
genes do not necessarily need to be pre-

• Able to treat otherwise
unaddressed types of
cancer (ex: refractory
NHL)
• Better able to penetrate
solid tumors
• Peptide-based do not need
to identify tumor antigens
• Target multiple antigens
• Long-term immune
memory against tumor
most likely achieved with
this strategy

• Cell-based: complex
manufacturing
• Gene and peptide-based:
limited by poor tissue
penetration (i.e. an
insufficient amount of
material reaches DCs in
vivo)

Clinical examples
• 79+ FDAapproved
monoclonal
antibodies:
cetuximab,
rituximab,
trastuzumab,
pembrolizumab
• 2 BiAbs for
cancer
treatment: antiCD19 x antiCD3
blinatumomab,
anti-EpCAM x
anti-CD3
catumaxomab
(withdrawn)
• Anti-CD19,
anti-CD20 and
anti-CD33
CAR-T
• Treatment:
Sipuleucel-T ex
vivo DC therapy
for prostate
cancer
• Prophylactic:
HPV and

Oncolytic
viruses

validated as tumor proteins can be
extracted directly from patients tumor
samples and loaded onto delivery vectors
• Cell-based: DCs are pre-activated against
tumor antigens ex vivo before reintroducing to patient

• Can be used as treatment
and prevention of cancer

• Therapeutic viruses bind tumor cellsurface viral receptors, take over cellular
mechanisms to self-replicate
• Selective high viral load in tumor causes
cells to burst tumor cells, releasing cell
death and tumor antigens (for the immune
system to recognize and become
activated)
• Viruses are also designed to secrete
immune-modulatory substances (ex: GMCSF)

• Can be used as treatment
and to induce long-term
memory
• Engages both innate and
adoptive immune
branches

Hepatitis B
vaccines

• Need to identify tumorspecific viral receptors

• Talimogene
Laherparepvec
(T-Vec) for
melanoma
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1.2 ANTIBODY-BASED THERAPIES
The following section summarizes four classes of antibody-based therapies of
interest in this thesis. Monoclonal antibodies (mAbs) eliminate tumor cells by either
inducing cell death and/or downregulating cell proliferation, engaging the innate immune
system (either cellular components or complement-mediated), and disengaging
immunosuppressing pathways. Antibody-drug conjugates (ADCs) harvest the tumorspecificity provided by mAbs and the high potency provided by small molecule drugs.
Bispecific antibodies target synergistic partners and engage specific immune cells (T
cells, NK cells for example). Finally, endogenous native antibodies that circulate in the
sera are also discussed as a niche group of antibodies of interest here. Compared to the
other cancer immunotherapies discussed in this thesis, antibody-based therapies are the
most widely studied to date, and the technologies for further development and
manufacturing are most solidly established.

1.2.1 Monoclonal antibodies (mAbs)
In the past two decades monoclonal antibodies have become increasingly of
interest, both as tools for scientific research and as therapeutics. Their exquisite
specificity allows us to bind and engage in a targeted manner. As research tools, this in
turn enables the detection of specific antigens and epitopes, for example in an ELISA
assay. As a therapeutic modality, monoclonal antibodies target drug delivery in a highly
specific manner and can induce mechanisms of action that are otherwise unattainable.
This is the main advantage of biologics over small molecule therapeutics. As of 2020, out
7

of the 570 monoclonal antibodies that have been tested in clinical trials, 79 have been
approved by the FDA and are currently available in the market, 30 of which are used in
cancer treatment6.
Antibody structure
Immunoglobulins
(IgGs) are made up of
two heavy chains and
two light chains. The
light chains are held
together by non-covalent
interactions and covalent
interchain disulfide
Figure 1.1. Antibody structure.

bonds. In both the heavy

and light chains, the C-terminal is made up of a constant region while the N-terminal part
is a variable region. Each light chain shown in green in Figure 1.1. has one variable and
one constant region, while each heavy chain shown in blue is made up of one variable
region and three constant regions. The N-terminal regions of one light chain and one
heavy chain form a structure known as a Fab region.
Each monoclonal antibody has two Fab regions, which allows binding to two
molecules of the targeted partner. CH2 and CH3, two of the three C-terminal constant
regions that make up each of the two heavy chains, form the Fc region. Finally, the
region located between the two Fabs and the Fc region is known as the hinge region and
8

made up of one constant region from each of the two heavy chains. It confers mAbs with
enough flexibility to bind two antigens simultaneously.
The Fc arm of a monoclonal antibody enables interactions with immune cells via
Fc receptors and other biological agents such as complement proteins. Different regions
within the Fc arm act as binding sites for different immunological agents. For example,
the lower hinge and adjacent region of the CH2 is critical for interaction with FcgRIIa,
while the CH2-CH3 hinge does not play a role7. The Fc arm is also a ligand for neonatal
Fc receptor (FcRn), which is expressed by endothelial and epithelial cells and is involved
in recycling of circulating IgGs. Within the Fc region of an antibody, the site for FcRn
binding is different from that of other Fc receptors. Here, binding to the Fc arm occurs at
the CH2-CH3 region8.
The Fc arm also determines the isotype of an antibody. Each species has different
antibody classifications. For example, murine IgGs are classified as IgG1, IgG2a, IgG2b
and IgG3. The following section details the different types of human antibodies and
subclasses in detail.
Finally, like all proteins, antibodies can also be modified post-translationally. For
example, glycosylation is a key post-translational modification that can impact antibody
stability and pharmacokinetics9. Unglycosylated antibodies are more prone to unfolding
and aggregation, and they are also cleared more quickly from the blood. Therapeutic
monoclonal antibodies, which are mostly Immunoglobulins G (IgGs), have one highly
conserved N-linked glycosylation at the Fc position N297, and 20% also have a second
9

site in the variable region on the heavy chains. Figure 1 on Haan et al shows the different
glycosylation sites available on different human antibodies10. For example, IgG3 contains
a third common site at N392, while IgAs and IgE have up to five or six total sites for
glycosylation, repectively.
Human antibody subclasses and isotypes
There are five types of human antibodies: IgM, IgA, IgD, IgE, and IgG. Each of
these antibody classes has a different function.
IgAs are found as monomers in the blood and make up 15% of the total
circulating antibodies. It also forms dimers when present in bowel fluids, saliva and nasal
fluids. In these locations, IgAs play a role in mucosal immunity against bacterial
infections. IgAs neutralize pathogens by aggregation or agglutination, especially when
they are in the dimer conformation, followed by clearance via peristalsis11. A second
defense mechanisms involves the inhibition of bacterial and viral adhesion to epithelial
cells12. IgAs are also present in breastmilk to help to protect newborns from bacterial and
viral infections.
IgDs are present on the surface of immature B cells. They start to be expressed
when B cells undergo differentiation and leave the bone barrow to settle at peripheral
lymphoid tissues. Once expressed, they play a role in the prevention of respiratory
infections as well as in the induction of B cell activation and antibody production.
IgEs are involved in allergic reactions. They are secreted by B cells and interact
with mas cells to amplify the immune response against allergens13. When IgEs bind on Fc
repectors on the the surface of mast cells, IL-4 is secreted and CD40-L is expressed.
10

CD40 receptor binding on B cells and wells as IL-4 binding to its receptor on B cells
induce further IgE expression. Their function is mostly needed at the site of immunogenic
reactions.
IgGs are the most abundant of human antibodies in the blood, accounting for 7075% of circulating antibodies and 10-20% of total plasma protein, and are classified as
IgG1, IgG2, IgG3, and IgG414. IgG1 is the most abundant out of the four subtypes.
Human IgGs are primarily involved in the immune system, and they are also the only
subclass that can pass through the placenta. The four subclasses are nearly 90% identical
in their amino acid sequence. Their structures differ most at the hinge regions and upper
CH2 domains14. For example, IgG3 has 62 amino acids in the hinge region (depending on
allotype) versus 12 for IgG2/IgG4 and 15 for IgG1. These structural differences also
result sin functional biases. For example, IgG3 is the best C1q binder, making this
subtype the best complement cascade mediator of the four. Each class has differential
expression of Fcg receptors as well as FcRn, as detailed on Table 1 in Vidarsson et al.
These differences in turn result in variable half-life, which is 21 days for IgG1, IgG2, and
IgG4, but can be as low as 7 days for some IgG3 allotypes.
Finally, IgMs are a made up of 5 IgG-like units (except for their Fc region is
made up of three CH sections as opposed to two) creating a pentamer. IgMs are first
produced by B cells when encountering a pathogen and are mainly present in the blood,
making up 10% of the total antibody in the blood. IgMs can activate complement
cascades and neutralize the influenza virus, for example11.
11

Therapeutic mechanisms of action in oncology

Figure 1.2. mAb mechanisms of action.

Anti-tumor effect via direct binding
There are multiple main ways in which monoclonal antibodies induce a
therapeutic effect on tumors. First, when they bind a specific protein on a cell surface,
monoclonal antibodies can directly block downstream pathways, which in turn downregulate pathological responses. The most challenging aspect of designing a mAb within
this category is elucidating the overriding interaction that needs to be targeted. Blocking
any one of the following steps or a subset of them can be sufficient to limit tumor
survival: ligand-receptor binding, homo- or hetero-dimerization, and modulation of
receptor expression.
For example, cetuximab is known to block the over-enhanced EGFR cell growth
signaling that commonly occurs in cancer cells by sterically hindering its ligand site
12

(Figure 1.2 A). This prevents the dimerization of the EGFR monomer into its active form.
Therapeutic anti-EGFR mAbs have also been designed to be better binders than the
natural ligand for EGFR, essentially outcompeting the ligand and preventing
dimerization. This mechanism of action has also been shown to be effective in blocking
HER-1 cell growth pathways which also drives tumor growth and survival. Trastuzumab
is another example of a mAb that blocks dimerization for HER-2 type receptors.
A more recently discovered mechanism of action that is primarily driven by direct
binding of the mAb to a tumor surface protein involves checkpoint inhibitor antibodies.
These block PD-1/PDL-1 and CTLA-4/B7 binding between cytotoxic T cells and tumor
cells. When PD-1 and CTLA-4 bind their ligands, cytotoxic T cell killing is
downregulated. Tumor cells overexpress these ligands to evade T cell killing. When
antibodies are administered to disrupt these pairs, these “breaks” are off, increasing T cell
cytotoxicity against tumor cells.
Antibody-dependent cell cytotoxicity (ADCC) and phagocytosis (ADP)
mAbs can also flag over components of the immune system via the Fc region, like
trastuzumab. In this case, macrophages and natural killer (NK) cells accumulate at the
tumor site and primarily responsible for clearing out the tumor cells (Figure 1.2 C). This
mechanism is known as antibody-dependent cell-mediated cytotoxicity (ADCC) and
antibody-dependent phagocytosis. More on this mechanism is described in a later section
regarding bispecific antibody mechanisms of action.
Complement-dependent cytotoxicity (CDC)
13

Monoclonal antibodies can also induce a complement cascade that causes tumor
cell lysis directly via the formation of membrane pores and by secreting proinflammatory mediators. Complement can also induce complement-dependent cellular
responses by recruiting phagocytotic cells15. Together, these mechanisms are called
complement-dependent cytotoxicity (CDC) as shown in Figure 1.2 B.
The complement cascade begins with IgG1 binding to its antigen on tumor
surface and forming a hexamer that C1q can bind to16. C2 and C4 cleavage follow,
producing membrane-bound C3 convertase. Subsequent cleavage of C3 to C3a and C3b
lads to the formation of C5 convertase, which is then cleaved into C5a and C5b. C6, C7
and C8 are then recruited and activated to catalyze C9 polymerization. The membrane
attack complex (MAC) is formed at this stage, which is essentially a pore on the cell
membrane. As more and more MAC are formed, cell lysis occurs due to membrane
destabilization.
Complement-mediated cellular responses are driven by a few mechanisms. The
release of C3a and C5a, which are strong anaphylatoxins, enables interaction with C3aR
and C5aR1 (CD88). These receptors are commonly expressed on multiple effector cells,
such as mast cells, macrophages, neutrophils, and dendritic cells. For example,
complement can directly modulate T cell response via CR1, CR2 (CD21), C1q, C3aR and
C5aR receptors.
An example of a mAb that induces CDC is rituximab, which binds to the altered
CD20 found on non-Hodgkin’s B cell lymphoma. The CDC-mediated mechanism of
action induced by rituximab is supported by various studies summarized by Zahavi et
14

al17. In a C1q-knock down in vivo study, rituximab induced almost no anti-tumor effect.
Second, morphisms at the C1q gene have been shown to corelate to patient response to
rituximab treatment. Finally, antibody optimization has been shown to improve the antiCD20 therapeutic effect of ofatumumab versus rituximab.
To exploit this mechanism of action, one of the most important factors is the
ability of the antibody to form a hexamer. This depends on various aspects: antigen
density on the tumor cell surface and the ability of the mAb to cluster multiple antigens
together. The latter further depends on the epitopes targeted and their accessibility and
the orientation of the mAb once bound. In the ofatumumab, it is known that this mAb is
able to bind CD20 closer to the cell membrane, favoring more efficient C1q binding16.
Additionally, both ofatumumab and rituximab have been shown to relocate CD20 into
lipid rafts, which helps the formation of antibody hexamers. This capability is believed to
lead to more CDC versus a third anti-CD20 mAb, obinituzumab, which is unable to
recruit CD20 into lipid rafts.
Additional mechanisms of action
Finally, mAbs can also bind to molecules secreted by tumors that are needed to
support the continued growth of tumor cells. For example, bevacizumab binds to VEGF
secreted by tumor cells. In doing so, it clears VEGF from circulation and prevents
binding to the receptor that would otherwise induce the formation of blood vessels
necessary to supply the tumor18.
Production methods
Hybridoma technology
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Figure 1.3. Hybridoma technology for monoclonal antibody production.

Monoclonal antibodies were first produced using hybridomas in 1975, and this
technique is still being used routinely19. To create a hybridoma, a mouse (or goat, rabbit,
rat, horse, donkey, etc) is repeatedly immunized with the antigen of interest. B cells are
harvested from the spleen of the immunized mouse and fused with immortal myeloma
cells to be able to proliferate continuously. The hybrid cells are then sorted for the
antibody of interest. This process can take weeks or months, it does not always yield the
desired antibody function and it generally suffers from low yields. For therapeutic
applications, the antibodies also need to be humanized, since the human immune system
would reject a mouse subtype. This is typically done by extracting the variable region
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from the resulting mAbs after immunizing a mouse onto a human IgG framework (see
below section on single B cell technology). Fully human mAbs can also be produced
using transgenic mice that have been genetically modified to express human IgG genes.
Once a clone is selected, therapeutic antibodies are most commonly expressed
using CHO and HEK293 cells, which provide the closest possible to native human
glycosylation patterns compared to bacterial, yeast and plant production methods. In
addition to the cell line used for production, the transfection method, expression vector
and promoter type can all influence the quality of antibody produced and the yield.
Phage and yeast display technologies
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Figure 1.4. Phage display technology for antibody identification.

A second technique to produce monoclonal antibodies involves using phage
display to select a clone against a desired target. In this method, a library of phage is
created with variants of the desired antibody. Each phage expresses the cloned variant on
its surface. The library is repeatedly sorted for optimized properties, including binding
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specificity and kinetics, until a clone is identified. The phage with desired properties is
then sequenced to obtain the amino acid code for the corresponding antibody. This
technology can be used on both monoclonal antibodies and the derivative fragments. One
of the downsides to this method is that it does not preserve native VH and VL pairing
since the clones are randomly mutated. Adalimumab (Humira) was produced using phage
display and it was the first fully human therapeutic mAb approved in 2002 for treating
rheumatoid arthritis6. As of 2020, nine human antibodies produced with phage display
have been FDA-approved.
The described technique can also be applied to yeast display as opposed to phage
display20. One advantage of using yeast versus phage is that the eukaryotic folding and
glycosylation patterns of the expressed proteins more closely matches human proteins.
Low affinity, high avidity clones may be more easily selected using yeast since there are
more copies expressed per yeast cell versus phage. However, due to the lower
transformation efficiency of yeast the diversity of the displayed antibody pool may not be
as high as with yeast (107-109 for yeast, up to 1011 for phage).
Single B cell production technology
This technology preserves the natural pairing between VH and VL as it occurs in
unmodified human B cells and produces a partially humanized mAb. It also allows the
preservation of native binding against targets that may be present in vivo but are difficult
to simulate in vitro, such as multimeric complexes, specific spatial conformations,
dynamic pH/ionic conditions etc.
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A pool of B cells is extracted from the peripheral blood or lymphoid tissues
(spleen) of an immunized mouse and sorted one by one for the desired characteristics21.
For example, to select B cells that specifically express IgGs against a known target,
antigen coated magnetic beads can be used for sorting. Then, the VH and VL regions from
the optimal clones are amplified and grafted onto human IgG frameworks for production.
The VH and VL regions can also be sequenced out of human clones when available.
Antibody fragments
Antibody fragments are smaller and modified portions of the classical IgG that
retain a strong and specific binding capability. One therapeutic advantage is enhanced
tumor penetration versus full-length mAbs22. Further, the smaller size also enables access
to difficult-to-access binding sites, such as pathogen glycoproteins and enzyme pockets.
On the other hand, fragments are limited by the following disadvantages: 1. they are
cleared faster in circulation and 2. the formats lacking an Fc region cannot induce
immune system recruitment and activation 3. nor can they undergo Fc recycling, which
further decreases circulation time. Several approaches have been developed to improve
the circulation half-life, including PEGylation, repeating peptide sequences, and
polysialylation23. Additionally, fusion to albumin binding domains or Fc domains are also
being investigated to slow down clearance in circulation24–26.
Another main advantage is the ability to produce fragments in bacterial and yeast
expression systems, which allows for faster and more accessible research. However,
fragments are not always as easy to express as mAbs and some types are more prone to
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aggregation. Some methods attempt to purify out of inclusion bodies, but this technique
does not always produce functional fragments.
A third advantage of smaller antibody fragments is that, due to their smaller size,
they cause less undesired immunogenicity and are less likely to non-specifically activate
the innate immune system.
Alternative antibody formats can generally be described in two categories: heavychain only formats and heavy and light chain formats. The main difference between these
two categories is that the IgG-like fragments contain an Fc region of some sort, while the
others don’t. The former includes camelid and shark single-domain antibodies, also
known as VHH or nanobodies and V-NARs, respectively, which are composed of only
one heavy chain. The latter category include Fabs, and its multimeric Fab2 and Fab3, as
well as single-chain variable fragments (scFvs) and its corresponding multimeric forms
such as diabody, tribody, and tetrabody.
Idarucizumab, abciximab, ranibizumab, and certolizumab pegol are examples of
FDA-approved antibody fragments. All three are Fab fragments and are not oncology
drugs. Caplacizumab is an example nanobody that has been approved and brolucizumab

Figure 1.5. Antibody fragment structures.
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is an approved scFv6.

Non-IgG protein scaffolds
In addition to IgG-derived fragments, other classes of small antibody-like binders
have been designed using multiple parental molecules. Some of the most developed
protein scaffolds include Affibodies, designed ankyrin repeat proteins (DARPins),
Anticalins, monobodies/Adnectins, and albumin-binding domains (ABDs). These classes
of small binders are single chains of amino acids folded into a single core. The parental
proteins for the first four are the Z domain of staphylococcal Protein A, ankyrin repeat
proteins, lipocalins, and the 10th fibronectin domain of human fibronectin, respectively.
Their overall size ranges between 7 and 21 kDa, but the sizes of their engineered binding
surfaces are similar to antibodies27.
Like IgG-derived fragments, these small scaffold binders allow better tumor
penetration versus full-length antibodies. Production of these small scaffold proteins is
also relatively simpler and more affordable than mammalian IgG production. In fact, the
smallest scaffolds can even be produced with solid phase peptide synthesis. Lastly, these
binders benefit from high thermal and storage stability as well as a lack of cysteines,
which can then be strategically introduced as a handle for maleimide chemistries.
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There are many examples of clinical applications within this subgroup. Affibodies
in particular have been extensively tested for therapeutic and imaging technologies28–30.
There are at least 40 antigens targeted by affibodies in the literature, commercially
available or in the clinic, most of which were developed using phage or staphylococcal
display. To create binders using this scaffold type, variants are typically produced by
random mutation of just 13 amino acids and the resulting affinities can be as low as
picomolar. Ge et al summarize a series of clinical trials results using affibodies as the
targeting moiety for PET and SPECT imaging as of 202130. In one example, 68Ga-ABY025, HER2-targeted gallium, was shown to increase tumor uptake specificity 2 to 4 h
after injection and allow better identification of low-to-medium HER2+ expressing
metastasis.

1.2.2 Antibody-drug conjugates (ADCs)
A further application of therapeutic monoclonal antibodies fuses small molecule
drugs to harvest both the specific targeting and favorable pharmacokinetics of mAbs and
the potent cytotoxicity of small molecule drugs. However, there are challenges associated
with this class of therapeutics too.
One of these challenges is the low efficacy predictability of the drug payload.
Small molecules that are used on their own as cancer therapeutics have failed in the clinic
when used as payload on ADCs. For example, methotrexate is a commonly used
chemotherapeutic that has failed to provide sufficient efficacy in clinical trials as part of
an ADC32. New drugs for ADCs are being investigated in labs and in the clinic with the
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hope that different mechanisms of actions can have a different effect on the ADC
therapeutic efficacy. Table 3 on Beck et al summarizes a variety of these new drug
payloads that have entered clinical trials32. An example of these newly developed drugs
for ADCs are benzodiazepines, which are naturally occurring antitumor antibiotics that
bind DNA in a sequence-specific manner. The advantage of this new class of small
molecule drugs is that they are not a substrate for MDR1, a protein that is commonly
involved in ADC resistance mechanisms that render other ADC therapies ineffective.
Second, the linker between the antibody and the drug needs to remain stable while
the ADC is in circulation, but it also needs to be able to release the drug inside the
intracellular compartment. If the linker is not able to release the drug once the ADC
crosses the cellular membrane, then it prevents the drug from working as intended. On
the other hand, if the linker comes apart during circulation, off-target toxicities are
observed as with traditional chemotherapeutics. This phenomenon has been reported with
maleimide type linkers in serum, especially with linkers attached at cysteine and lysine
residues33. A few strategies have been reported to prevent this premature release,
including conditionally released linkers as well as the enhancement and limitation of the
bystander effect. The former uses cleavable linkers to release the drug only once the
ADC has reached the cytoplasm. Examples include proteolysis-sensitive linkers, such as
those degraded by lysosomal protein cathepsin B, and pH-sensitive linkers, such as
hydrazone32. The latter relies on a targeted ADC inducing tumor cytolysis on both the
cells that express the targeted antigen as well as neighboring cells that don’t necessarily
express the chosen antigen. The linker charge has been found to determine the bystander
24

potency35. For example, ADCs that include MMAE are better able to kill neighboring
cells. Cleavage of the ADC releases neutral-charged MMAE which can better cross
hydrophobic lipid membranes.
Finally, control of the conjugation site and the small molecule payload per IgG
control is not trivial as most ADCs were initially conjugated using non-specific
maleimide or thiol chemistries. While the first FDA-approved ADCs were created with
non-specific methods, there are multiple problems with this type of techniques. The
heterogenous product is made up of molecules with varying drug-to-antibody ratios
(DARs), and any subgroup with equal DARs is likely conjugated at different sites. This is
problematic because each molecule will behave differently in vivo. For example, varying
DARs lead to various degrees of efficacy and antibody recycling will be different
depending on the site of modification. Essentially, each subset of molecules will have
different properties regarding pharmacokinetics, toxicities, stability, antigen binding, and
drug release36. There has been significant advancement in creating site-specific
modifications that avoid these problems, as summarized by Table 4 of Beck et al32. The
following subsections dive deeper into various methods to conjugate drugs onto
antibodies.
Despite the associated challenges, there were at least 60 ADCs being tested in
clinical trials as of 201732. Additionally, there are already 4 ADCs commercially
available as summarized by Khongorzul et al, the first one being approved in 2000. They
each target different antigens, including HER2 and CD22, and they carry a variety of
drug payloads that act as DNA damaging agents and microtubule disruptors35.
25

Selective engineering of chemically reactive amino acids
One strategy for site-selective drug conjugation relies on selective engineering of
cysteines, such as the THIOMAb technology developed by Genentech35. This method
involves selecting a specific site for a cysteine insertion which can then be used as a
thiol/maleimide handle preferentially over other reactive amino acids. The cysteines are
inserted at sites with selective solvent accessibility and local charge32. The sites are also
chosen to minimize disturbance on antigen binding. In the THIOMAb example, the
inserted cysteine is initially protected or capped. Following TCEP or DTT reduction and
oxidation via CuSO4 or dehydro-ascorbic acid (dhAA), the cysteines become available
for maleimide conjugation of the desired small molecule drug.
One downside of this strategy is that it needs to be optimized for every
antibody/drug pair as each drug exhibits different solvent solubilities and charges,
requiring different insertion sites. Further, the insertion sites are restricted to areas that
are preferentially reactive the other residues.
Similarly, another strategy introduces an amino-terminal engineered serine (Nterm of the light or heavy chain) that allows for site-selective oxidation and ligation. For
example, MedImmune has created homogenous ADCs by using the hydroxyl groups at
the amino terminus for mild oxidation, followed by oxime ligation32.
Enzymatic methods using peptide substrates
Site-specific conjugation can also be done by inserting peptide tags into the
antibody sequence. These peptide motifs are recognized by enzymes, including
transglutaminases and sortases, and used as substrate for amine conjugation. For
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example, ADCs have been produced using Sortase-mediated enzymatic ligation via
LPETG-modified mAbs and GGG-tagged drugs35. Another example utilizes bacterial
transglutaminases to catalyze the formation of a covalent bond between a glutamine side
chain and a primary amine.
While this method is site-specific, controlling the extent of the reaction is not
straightforward. An example reported by Innate Pharma used a microbial
transglutaminase to load auristatin onto an IgG135. Here, only 50-50% of the heavy
chains were modified. To increase the percent of modified heavy chains, they instead
modified the antibodies with a smaller azido-amine, followed by click chemistry to attach
the drug. This modular strategy resulted in over 95% modification.
Another challenge with this method is demonstrated by example summarized by
Agarwal et al. Here, a transglutaminase from Streptoverticillium mobaraense is used to
introduce small molecules into the inserted LLQGA motif41. A study tested the optimal
site for incorporation within the antibody sequence. The two best sites that led to a DAR
of nearly two were compared in rats in regards to the pharmacokinetics. One of the two
exhibited significantly faster clearance times.
Modifications at glycosylation sites
This method exploits the inherent site-specificity of the highly conserved
glycosylation site in human IgGs (N297 in the CH2 domain). Besides its broad
applicability to all human IgGs, an advantage of this method is that the site is sufficiently
far from the antigen-binding site, rendering antibody binding disturbances unlikely.
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One of the difficulties is that glycosylation is not homogenous, leading to low
extents of modification. A recently developed technique to overcome this challenge
optimizes homo-glycosylation to produce IgGs in that are majorly modified with
fucosylated N-acetylglucosamine (GlcNAc)42. The fucosylated IgG is oxidized to a
carboxylic acid and an aldehyde. The resulting aldehyde is the used for hydrazone
conjugation of the small molecule drug.
One aspect of this method that still needs to be elucidated is how the masking of
the glycosylation site affects antibody recycling and, therefore, the pharmacokinetics of
the ADC. As reviewed in the antibody fragments section, there are multiple tools
available to increase circulation time as needed.
Unnatural amino acid incorporation
Another solution for site-specific bioconjugation incorporates unnatural amino
acids (UAAs) into the antibody sequence. To do so, a mutant tRNA/aminoacyl-tRNA
synthetase is used to load an unnatural amino acid at the amber stop codon TAG.
Unnatural amino acids are not typically found on naturally existing polypeptide chains.
They can be secondary metabolites from bacteria, fungi, plants or other microorganisms
or they are synthesized chemically. In the context of ADC conjugation, UAAs are used as
a bio-orthogonal reactive handle to load the small molecule drug site-specifically.
One example in this category incorporates p-acetylphenylalanine into trastuzumab
during mammalian expression, followed by oxime conjugation of an aminooxy-auristatin
F via the available ketone42. Here, in vitro evaluation of three different conjugation sites
showed no difference in anti-HER2 activity. In vivo, the ADCs produced using UAAs
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were found to be more effective than the same ADC produced via non-specific
chemistries with DAR larger by a factor of two42.
Mammalian production using UAAs is technically complex, and the yields can be
10X lower than typical production titiers43. This is because the machinery required to
load the UAA onto the tRNA needs to be expressed at sufficiently high concentrations in
order to produce the desired protein effectively. Further, amber suppression in
mammalian systems is convoluted by the high frequency of naturally existing amber stop
codons.
Cell-free protein synthesis is a more recently developed method for UAA
incorporation. This method uses clarified E. coli lysate as the medium for expressing
proteins with UAAs. An advantage here is that expression conditions can be varied and
screened with a relatively higher throughput versus mammalian or traditional bacterial
culturing. One example compared 1760 variants of the tRNA synthetase to screen for
optimal p-axidolphenylalanine incorporation (in GFP, but this could be used for
antibodies too). ADCs produced with the top variants identified in the screen were
characterized with a DAR of 1.9 and were found to exhibit expected in vivo activity42. It
is worth mentioning that one main disadvantage of this system is the lack of
glycosylation, which was previously discussed in this thesis as an important factor that
dictates FcRn recycling and pharmacokinetics.

1.2.3 Bispecific antibodies
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This format of therapeutics enables simultaneous binding to two different antigens
or epitopes. This capability in turn facilitates access to otherwise inaccessible
mechanisms of action as described in the following section.
Mechanisms of action
Interference of receptor signaling
This section describes the blocking of one or multiple cell growth and survival
pathways that are typically over-stimulated in cancer. With a bispecific antibody, parallel
and synergistic pathways can be blocked simultaneously44. Multiple different initiating
receptors for a single pathway can also be targeted at once to block heterodimerization
and limit downstream activity more effectively45,46.
Herceptin receptors are a subgroup of receptor tyrosine kinases (RTKs) and
includes HER1/EGFR, HER2, HER3, and HER4. These receptors act as EGFR-ligand
receptors when they are in a heterodimer conformation (HER1 and HER2, for example).
The high degree of crosstalk among these receptors founds the rationale for bispecific
antibodies that target two or more of them simultaneously. This concept has been tested
in the clinic, but no candidates have obtained approval yet.
An example of this mechanism is illustrated by Merrimack’s MM111 drug
candidate which is composed of two scFvs that target HER2 and HER347. Simultaneously
blocking both HER2 and HER3 provides an additional therapeutic window versus
blocking only HER2. Another example involves blocking both HER2 and insulin-like
growth factor (IGF)-1R, which is an RTK outside of the HER family48. The idea here is
to block two parallel cell growth pathways to achieve greater efficacy. A third example,
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MEDH7945A, blocks EGFR and HER3 simultaneously with the hopes of completely
inhibiting MAPK and AKT signaling to stop cell growth more abruptly.
Eli Lilly’s LY3164530 is another interesting example of a mechanism of action
uniquely achieved by bispecific antibodies49,50. This drug candidate was designed to bind
both growth factor receptors HER1 and c-Met. A bispecific format is needed in this case,
as opposed to co-administration of two different monoclonal antibodies targeting each of
the bispecfic’s antigens, because both pathways are turned on via IgG-dimerization. The
bispecific format prohibits this potential issue by binding only to one of each kind.
A final example outside of the HER family of RTKs blocks two TNF family
receptors, TNF-Related Apoptosis Inducing Ligand Receptor-2 (RAIL-R2) and
Lymphotoxin-beta Receptor (LTβR). These are expressed on the surface of epithelial
tumor cells and, when blocked, were found to produce a greater anti-tumor effect versus
co-administration of the parental binders51.
Immune cell recruitment
Bispecific antibodies can recruit cellular immune components that don’t normally
interact with antibodies, such as cytotoxic T cells, and they can also potentiate the
recruitment of NK cells and macrophages. Briefly, bispecific antibodies bridge cancer
and effector cells.
The two bispecific antibodies for cancer treatment that have been approved by the
FDA to date fall within this category. For example, blinatunomab is a 55 kDa bispecific
therapeutic made up of two small fragments that target CD19 and CD3. It lacks an Fc
region and has a short half life (~1hr in vivo)45. Much of the current interest in T cell
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redirecting bispecifics stems from the clinical success recorded with blinatumomab to
date.
T cell recruitment bispecific antibodies
For T cell recruitment, the goal is to induce T cell expansion and activation (Figure 1.6).
T cells are activated by binding to CD3e in the T cell receptor (TCR) complex, which
obliterates MCH compatibility and induces T cell activation regardless of the TCR
epitope specificity45. This creates a forced synapse that drives T cell cytolysis via the
native cytotoxic T cell mechanisms such as the release of granzymes, which are
proteolytic enzymes, and perforins, which are membrane-disrupting proteins, leading to
cell lysis. Multiple factors need to be optimized in this format to achieve sufficient
therapeutic efficiency: Fc interactions, T cell binding, and tumor binding.

Figure 1.6. T cell recruitment bispecific antibody mechanism of action.

First, the risk of cytokine release storm (CRS) can be minimized via protein
engineering of the Fc region (if one is present in a given bispecific format). This lesson
was first learned with monoclonal anti-CD3 OKT3. Here, a major mechanism leading to
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CRS was identified to be the clustering of CD3 on T cells through Fc-binding to other
immune cells45. A second version of OKT3 was engineered to reduce FcgR binding and
was found to significantly reduce the risk of CRS. A second example of this reduction of
CRS risk via limiting FcgR binding has also been recorded with anti-EpCAM, anti-CD3
catumaxomab.
Second, T cell targeting can also be optimized to potentiate therapeutic efficacy.
Multiple studies have demonstrated the effects of the anti-CD3 binding affinity and
valency on the biodistribution and activity of T cell redirecting bispecifics. Although in
vitro cytotoxicity improves with stronger binding affinities (KD less than 1 nM), in vivo
tumor accumulation is better with more moderate binding affinities (50 through 200m
nM)45. The ongoing hypothesis for this phenomenon is that lower CD3 affinities decrease
the clearance of the bispecific from plasma as well as the trapping in T cell rich organs
such as the spleen and lymph nodes. In other words, the “sponging” effect is diminished
when CD3 binding is not as strong. Similarly, although bivalency might seem a better
choice over monovalency, it’s been found that monovalent anti-CD3 can induce
sufficient T cell activation while avoiding CD3 crosslinking on the T cell surface that can
lead to CRS. It is also worth noting that additional T cell targets are also being studied in
addition to CD3. These include αβTCR and T cell surface glycoprotein CD5 to name a
few.
Finally, tumor targeting can also impact overall therapeutic efficacy. Here, TCR
formation can be driven by antigen expression density, but it is not necessarily a limiting
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factor. Examples of density correlations to therapeutic efficacy have been reported with
carcinoembryonic antigen (CEA), CD33, and HER2, while no correlation has also been
reported with others such as prostate-specific membrane antigen (PSMA)45. A minimum
antigen density does seem to exist, but this also varies among targets and has been
reported to range greatly between 50 and 10,000 sites per tumor cell. In addition to
antigen density, its size and fluidity on the cell membrane as well as the distance between
the epitope and the cell membrane have also been reported to impact therapeutic efficacy.
NK-redirecting bispecific antibodies
Similar to CD3 binding on T cells, bispecifics for NK redirecting commonly bind
to surface CD16. Here, alternative NK targets have also been investigated, including
NKp30, NKp46, NKG2D, and DNAM-152. NK-mediated killing is primarily driven by
the release of perforin and granzymes. Here, an immunological synapse is also formed, as
with T cells, followed by the exocytosis of granules containing perforin and granzymes.
Further, NK cells can also secrete tumor necrosis factors (TNF) and cell death ligands
such as Fas and TNF-related apoptosis-inducing ligand (TRAIL). These ligands bind
their respective receptors on tumor cells to activate a caspase enzymatic cascade that
results in cell apoptosis. Finally, NK cells also secrete pro-inflammatory cytokines and
chemokines, including IFNg, IL-6, and GM-CSF, that can support the anti-tumor effect
and amplify the activation of both innate and adaptive immune responses52.
The accumulated knowledge to date on the mechanisms of actions of bispecific
antibodies has led to the development of trispecific antibodies or trispecific killer
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engagers (TriKEs). For example, T cell redirecting trispecifics have been designed to
bind both CD3 and CD28, in addition to the tumor antigen53. Similarly, a tumor-targeted
anti-CD16 NK redirecting bispecific was converted into a TriKE by conjugating IL-15 as
an activation co-factor and shown to outperform the bispecific54.
Forced proteins associations
This mechanism of action is the least commonly reported, but an interesting one
nonetheless. An example of this unique application (outside of cancer treatment) is the
forced assembly of the coagulation Xase complex. Here, a bispecific connects FXIa and
FX to overcome FVIII deficiency in Hemophilia A. The Roche drug candidate
emicizumab is in Phase 3 currently and expected to be filed in 2022.
Therapeutic formats
There are at least 60 formats for bispecific antibodies and they can be divided into
two categories: IgG-like and fragment-based55. Figure 1 in Spiess et al depicts many
examples of the formats available as of 2015. The advantages and disadvantages here are
similar to those of mAbs versus antibody fragments.
Full-length IgG-like bispecifics
Early methods: the heavy chain-pairing problem
One of the first methods used to produce full-length bispecifics is the coexpression of two different pairs of light/heavy chain in a single host. Once expressed, if
they pair up correctly the resulting bispecific yields one site against each of the two
desired targets. However, it is difficult to control the pairing, yielding low amounts of the
desired bispecific. It is particularly difficult to remove the homodimer unwanted products
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because they are identical in size. Catumaxomab (anti-CD3, anti-EpCAM) is an FDAapproved example that was produced using this method. In this case, one heavy chain is
rat IgG2b and the second one is mouse IgG2a. Therefore, purification is possible as only
the mouse heavy chain is captured with Protein A56.
“Knobs-into-holes”: engineered heavy chain-pairing
To overcome the heavy chain-paring problem, heavy chains can be engineered to
avoid homodimerization. Heavy chain-paring is mediated by one CH3 alone. The concept
relies on mutating these regions to favor heterodimerization over homodimerization. In
this strategy, one heavy chain is mutated to favor the “knob” configuration (example:
T366W mutation), while they second heavy chain is pushed into the “hole” configuration
(example mutations: T366S, L368A, and Y407V). Here, phage display was used to
identify the required mutations to optimize heterodimerization.
Overcoming the light chain-pairing problem
One way to avoid improper light chain-pairing is to utilize antibodies with a
common light chain. These types of antibodies can be selected using phage display or
transgenic mice with a single light chain.
A more widely used method is to produce each heavy/light chain pair in a
different host, purify them individually, and then mix them allowing the “knobs-andholes” step to form a bispecific. The main advantage here is that each light chain can be
tuned to its required specificity and affinity without the limiting common chain scaffold.
However, this method is typically more laborious, expensive and adds complexity to the
manufacturing.
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CrossMab uses domain crossovers for the light chains and “knobs-into-holes” for
the heavy chains. Domain crossover creates two asymmetrical Fabs by swapping either
the variable or constant domains between the light and heavy chains. The asymmetry
prevents the light chain against one target from pairing up with the light chain against the
second target.
The IgG-like bispecific format known as “LUZ-Y” is second example of a
technology that overcomes light chain-pairing. Here, a peptide link forces cognate pairing
between the corresponding light and heavy chains. Formation of the full-length IgG is
achieved with a leucine zipper that optimizes heterodimerization and is subsequently
removed via proteolysis.
Overcoming both heavy and light chain-pairing with a single technology
An additional format utilizes phage display to identify “two-in-one” or Dual
Action Fab (DAF) antibodies. For example, an anti-HER monospecific antibody was
further engineered with phage display to preserve its original capability and also be able
to bind to VGEF57. Further, a “four-in-one” antibody can be created by combining this
technology with CrossMab58.
IgGs appended with additional IgG-derived and non-IgG derived domains
To confer bi- or multispecificity, one or two additional light chains or scFvs can
be fused onto the C- or N-terminal of an IgG. The dual variable domain IgG (DVD-Ig) is
an example of this format that made it into the clinic. Here, a VH and VL of a second
antibody are appended onto the Fab region of an IgG, creating a bivalent bispecific. One
advantage is the ability to bind all four simultaneously to provide higher specificity. This
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can in turn enable binding to low abundance proteins and longer dosing times. Compared
to the previous IgG-like formats discussed, this example also provides more physical
space between the two desired targets and enhanced molecular flexibility. The challenge
with this strategy is ensuring that parental binding at the light chains is not affected.
Similarly, non-IgG scaffold binders can also be fused to antibodies to create
bispecific therapeutics. To demonstrate the potential for multi-binders using IgG fusions
with scaffold binders, LaFleur et al created penta-specific fusion zybodies. These IgG
fusions with a combination of Affibodies, cysteine-knot based Knottins and peptides
were shown to effectively engage ErbB2, EGFR, IGF-1R, Ang2 and integrin αvβ359.
Using this method, bispecific antibodies were also produced without much of a difference
observed in the binding affinities compared to the parental units. In another example,
anti-HER2 Fynomers were fused to anti-CD3 mAbs, creating T cell recruiting bispecifics
in two different orientations. These were shown to bind HER2+ tumor cells and induce
tumor cytolysis64.
Non-IgG-like bispecifics: fragments- and scaffold-based
The second major category of bispecific formats usually lacks some or all of the
IgG constant regions. The most utilized building block in this format is the scFv
fragment, in which a short peptide linker forces VH-VL or VL-VH conformation. Two
scFvs can be co-expressed (diabody) and stabilized with a disulfide bond (DART) or
expressed in tandem (like the BiTE format). Two tandem scFvs is a popular format that
has advance into the clinic with blinatumomab, anti-CD3 x anti-CD19. Two pairs of
scFvs can also be fused in tandem to create a tetravalent diabody (TandAb). Bispecfics
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created using single domain antibodies are further reduced in size. These building units
are more readily combined and provide greater stability and expression yield. They are
typically derived from camelids and sharks, as discussed in previous sections.
Non-IgG-like bispecifics have also been produced using scaffold proteins derived
off alternative molecules. For example, an anti-HER2 and anti-EpCAM bispecific made
up of two DARPin molecules60. In this strategy, the bispecific was expressed by an
oncolytic measles-based virus as a targeting vector. In another example, an anti-HER2,
anti-EGFR bispecific molecules was designed using two Affibodies fused via three
GGGGS linkers61. Another example utilizing fibronectin-based scaffolds was reported by
Emanuel et al. This construct targets GFR and IGF-1R and uses a flexible 20 amino acid
linker between the two domains. It was shown to inhibit tumor growth in vivo better than
the co-administration of the unlinked domains62.
Generally, in addition to their improved expression yield, stability and stability,
the differentiating factors for these non-IgG like bispecifics include alternative delivery
routes that are otherwise impossible with full-length bispecifics. For example, pulmonary
delivery has been reported using Anticalins (PRS-060; NCT03384290) and Kunitz
domains (NCT00455767)63. Second, these smaller targeting domains are better suited for
intracellular delivery of protein therapeutics. They exhibit better penetration versus IgGlike bispecifics and can be more easily packaged in delivery systems, such as lipid
nanoparticles. Finally, the ability to utilize solid phase peptide synthesis for the domains
that are small enough permits the possibility of incorporating multiple uncommon and
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unnatural amino acids. For example, different chirality can be used to target a set of
antigens that is currently inaccessible.
Shortcomings and challenges with available bispecific formats
Despite many successful examples, only 14 of the over 60 formats reported to
date have advanced in the clinic. The most widely agreed on challenges are summarized
again as follows:
Development challenges
-

Long optimization times and high technical complexity for each desired bispecific
pair

-

Difficult to preserve parental specificities and affinities

-

Low expression yield

-

Presence of unwanted side products and difficult removal

-

Low stability and solubility

Effector function difficulties
-

Formats lacking Fc regions cannot induce ADCC, CDC

-

Fragments-based formats do not always allow sufficient spacing and flexibility

-

Functional variability hinges significantly on orientation chosen. In one
outstanding example, appending an scFv onto the C-term of either the light or
heavy chain resulted in potent or almost no activity, respectively64.

Lacking and undetectable therapeutic targets
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Despite our ability to select an antibody or antibody fragment against theoretically
any target using technologies such as phage display, there are many therapeutic
applications in which we lack the biological knowledge and/or the tools needed to
unearth druggable therapeutic targets. In oncology in particular the field is currently
facing many challenges associated with antigen heterogeneity, antigen loss, and naked
tumors for which we cannot detect druggable targets. This challenge is discussed in detail
in later sections.

1.2.4 Native antibodies: endogenous anti-tumor autoantibodies
A niche class of antibodies in this thesis involves the naturally occurring
circulating antibodies that are produced by the immune system in response to tumor
growth. Anti-tumor autoantibodies have primarily been investigated in the context of
diagnosis and prognosis patterns, with some reported as useful markers. They have been
reported to target tumor associated antigens in a variety of murine and human cancers,
highlighting their potential as targeting moieties and imaging agents61,62. Tsou et al, for
example, points out the usability of serum autoantibodies to design monoclonal antibody
therapies as well as cancer vaccination strategies.
The following sections summarizes data supporting the tumor specificity of
autoantibodies, circulating as well as produced at the site of tumor growth, and their
potential as diagnostics and therapeutics.
Evidence of tumor specific autoantibodies
Circulating autoantibodies
41

Self-antigens
Many of the reported autoantibodies are targeted against self-antigens, as opposed
to neoantigens63. This review by Bei et al summarizes many examples of tumor proteins
targeted by autoantibodies in patients diagnosed with different types of cancer. The selfantigens summarized here include nuclear proteins as well as membrane proteins. A
second by Piura et al review further expands on the self-antigens targeted by cancer
autoantibodies64. Further, Merbl et al reported tumor-specific autoantibodies in a
syngeneic Lewis lung carcinoma murine model65. Among the tumor-associated antigens
found to be targeted by circulating autoantibodies were p53, cytokeratin, carbonic
anhydrases, and tyrosinase. Similarly, Chen et al reported new bands detected in Western
blots of tumors probed with the serum of rats treated with PDT66.
In humans, Hoshino et al found that the autoantibodies of 100 gastric cancer
patients targeted at least one of a panel of six tumor-associated antigens including p53,
heat shock protein 70, HCC-22-5, peroxiredoxin VI, KM-HN-1, and p9067. In breast
cancer, Bassaro et al found that 20% of 30 known cancer-related proteins had an elevated
autoantibody response68. In another clinical example, Milne et al reported 26% (9/35) of
ovarian cancer patients were found to have circulating IgG autoantibodies against NYESO-169. In these patients, the tumor cells were also found to express NY-ESO-1.
Interestingly, this study also reported an increase in tumor infiltrating T cells in the
patients with autoantibodies against NY-ESO-1. Additional studies have also reported
high titers of circulating autoantibodies against NY-ESO-1 in melanoma patients70.
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Interestingly, these tumor-specific autoantibodies were found to be sialylated at a higher
frequency than the circulating antibodies of healthy controls.
Another example of a well-studied tumor antigen targeted by circulating
autoantibodies is underglycosylated mucin 1 (MUC-1). Antibodies against this antigen
have been found in the sera of patients diagnosed with pancreatic, breast, gastric, lung,
and ovarian cancers, and they serve as a marker of improved prognosis71.
Neoantigens
Still, there are at least a few reports that have identified autoantibodies targeting
neoantigens72–74. For example, Ishikawa et al found a autoantibodies targeting a specific
frameshift mutation in the peptides derived from tumor tissue of patients diagnosed with
colorectal cancer with microsatellite instability. Similarly, Fischer et al analyzed the
sequences of peptides targeted by the circulating autoantibodies of cancer patients. These
peptides were not found to have any homology to known peptides, and they were in fact
determined to be produced via alternative splicing using alternative splice codons.
Finally, although reactivity of endogenous autoantibodies was not tested in this study,
Kahles et al provides a thorough analysis of alternative splicing events identified in over
8,000 patients with 32 different types of cancers. Together, these suggests that there may
be more autoantibodies targeting neoantigens than what is currently reported in the
literature.
Autoantibodies detected within tumor tissues
In addition to circulating autoantibodies, there have also been reports of
autoantibodies detected on murine tumor tissue. For example, Rich et al investigated
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multiple murine models and found up to ten times more autoantibody bound on tumor
tissue versus other major organs in a syngeneic triple negative breast cancer model75.
Preise et al also conducted a similar experiment to demonstrate tumor binding of murine
autoantibodies76. Here, Figure 6 shows: 1. the appearance of new tumor antigens
identified by serum autoantibodies one week after treatment, 2. B cell recruitment within
tumor tissue, and 3. Tumor binding specificity of the circulating IgGs.
In humans, a recently published review further expands on our current knowledge
of tumor-specific autoantibodies reported to be produced at the site of tumor growth71.
For example, Montfort et al reports on the infiltration of B cells and production of tumorspecific antibodies at high grade serous ovarian metastases77. The importance of the
infiltrating B cells is also highlighted by a murine study in which B cell depletion showed
more aggressive tumor growth. Another example by Pavoni et al found the antibodies
secreted by infiltrating B cells within melanoma tissue to be highly tumor-specific78.
Finally, a similar study found the same trend in infiltrating ductal carcinoma of the
breast79.
Diagnostic autoantibodies
Growing interest in the detection of antibodies as a diagnostic for cancer
stems from the need to diagnose at earlier stages, preferably before symptoms become
apparent and before progression into uncurable stages. One of the challenges to achieve
this is the low specificity for any individual marker as well as the overlap among multiple
cancers (i.e. detection of a subset of antigens does not narrow down which cancer the
patient will develop). For example, Chapman et al tested the serum of 97 breast cancer
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patients and 40 ductal carcinomas in situ (DCIS) for seven antigens: HER2, c-myc, p53,
BRCA1, BRCA2, NY-ESO01 and MUC1. Even though all of the markers exhibited
relatively high specificities ranging 91% to 98%, the individual sensitivities were was
low as 3% to 24%80. When a panel of the autoantigens was considered, the sensitivity
increased significantly up to 64% for breast cancer and 45% for DCIS.
Lung cancer detection offers additional examples of the potential of
autoantibodies as a diagnostic tool. For example, Brichory et al found that 60% of
patients in their screen had autoantibodies that reacted against glycosylated annexin I and
II, while healthy controls exhibited no reaction81. Additional examples similar to
Brichory are thoroughly summarized by Yadav et al82. A more recent systemic review
reanalyzed the data from 31 articles reporting single autoantibody biomarkers and 39
articles reporting multiple biomarkers83. The main takeaway from this study is that a
panel of 7 biomarkers is able to achieve 40% sensitivity and 91% specificity for earlystage lung cancer.
Tumor-specific autoantibodies have also been evaluated as a diagnostic
tool in the context of ovarian cancer. Fortner et al conducts a systematic review on 29
autoantibody studies, the majority of which were hypothesis-driven (i.e. they evaluated
the specificity of autoantibodies against target tumor antigens)84. Some of the screening
studies used serological expression cloning (SEREX) and protein arrays. The metaanalysis found two antigens targeted by autoantibodies to display relatively high
sensitivity (89.5% and 89%), yet their specificity was relatively lower (80% and 75%).
Further, they found anti-IL8 autoantibodies to detect stage I-II ovarian cancer, which is
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currently under-detected, with a sensitivity of 65% at 98% specificity. These findings
highlight the significant impact that autoantibodies could have as diagnostics, particularly
in cancers that are currently detected at later, uncurable stages such as ovarian.
Therapeutic anti-tumor effect of autoantibodies in murine models
In mice, Yu et al found tumor-specific autoantibodies in mice immunized with
irradiated syngeneic colorectal tumor cells85. Following immunization, mice challenged
with the syngeneic tumor showed dampened and lesser overall tumor re-growth
compared to naïve mice85. Similarly, Preise et al report an anti-tumor effect induced by
the serum autoantibodies found in the same syngeneic colorectal model after
photodynamic therapy (PDT)76.
Further, autoantibodies produced following PDT have also recently been reported
to induce anti-tumor effects via complement activation as well as macrophage-mediated,
antibody-dependent anti-tumor activity86. Interestingly, autoantibodies collected from the
serum of a murine colorectal model were also protective against a murine triple negative
breast cancer model, suggesting an overlap of tumor antigens.
Another report of the therapeutic potential associated with autoantibodies was
completed by Lin et al87. Here, a small molecule termed P4N is found to inhibit tumor
growth in a murine colorectal cancer, and an increase in the titer and quality of
endogenous circulating autoantibodies is corelated to this anti-tumor effect. Passive
transfer of the autoantibodies suppressed lung metastasis and prolonged the survival of
tumor-bearing mice. In this example, the autoantibodies were found to target two tumor
surface proteins: glucose-regulated protein (GRP78) and F1F0 ATP synthase.
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1.3 CELLULAR THERAPIES
An alternative approach to antibody-based cancer immunotherapy has become an
increasingly popular field in recent years. The development of CAR-T therapy has
fundamentally changed how we treat cancer by adding an entirely new modality to the
treatment toolkit. This technology has been in part made possible by the development of
antibody fragments such as scFvs and improved gene editing techniques.

1.3.1 Chimeric Antigen Receptor (CAR) T cell Therapy
In this personalized treatment, patient T cells are extracted from the blood and
genetically modified to overexpress a chimeric antigen receptor (CAR). The first version
of this technology expresses a fused receptor that includes an extracellular anti-tumor
scFv (for example: anti-CD19) and an intracellular CD3z stimulatory domain. Further
developed versions now include multiple costimulatory domains, such as a CD28 and 41BB. The concept essentially pre-charges cytotoxic T cells with the ability to target an
identified and pre-validated tumor target. Once the scFv engages with its designed target,
the chimeric receptor sends down the signal needed to activate T cell activation and
expansion. The activated T cells then proceed to eliminate tumor cells via the native T
cell killing mechanism: releasing perforin and granzyme B to induce apoptosis and
secreting cytokines IFN-g and IL-2 for signal amplification.
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One main downside associated with the clinical application of CAR-T is the
highly complex manufacturing. To alleviate this bottleneck, universal T cell sources are
being investigated via multiple strategies. Additionally, undesired side effects are often
observed in patients, including deadly toxicities. Antigen loss continues to limit this
strategy as well. In some cases, initial treatment results in remission, but refractory
tumors are common post treatment.

1.3.2 CAR-natural killer (NK) cell treatment
Clinical success with CAR-T treatment has also led do the development of
additional cellular therapies. This format utilizes natural killer (NK) cells in the same
scheme as CAR-T. One unique advantage of this format has been found in clinical
development as CAR-NK and unmodified NKs have been found to cause less ontarget/off-tumor toxicity to normal tissues, perhaps due the limited circulation lifespan, as
well as reduced graft-versus-host (GVHD) risk88. Compared to T cells, NK cells naturally
secrete cytokines that are less likely to cause cytokine release storm and neurotoxicity.
Moreover, CAR-NK cells provide an additional CAR-independent tumor-killing
mechanism since they preserve their native anti-tumor mechanisms driven by NCRs,
NKG2D, co-stimulatory receptor DNAM-1 (CD226), and certain activating KIRs
(KIR2DS1, KIR2DS4 and KIR2DL4) as well as CD16-mediated ADCC. This is thought
to help eliminate cells that express the target antigen at lower concentrations, which can
make total eradication of a heterogeneous tumor challenging.
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Finally, the reduced risk for GHVD facilitates the creation of a universal source
for NK cells such as NK92 cell lines, peripheral blood mononuclear cells (PBMCs),
umbilical cord blood (UCB), and induced pluripotent stem cells (iPSCs)89. While CARNKs provide an additional CAR-independent tumor killing mechanism and there are
more facile strategies to source NKs, there is still a need to identify a highly expressed
antigen, and the tumors can still undergo antigen loss.

1.4 ANTI-CANCER VACCINES
An additional category of alternative cancer immunotherapy involved vaccination
either as prophylactic or post-diagnosis treatment. Within this category, there are multiple
types of vaccines, including cell-based vaccines, gene vaccines, and peptide-based
vaccines. Each type provides different advantages and disadvantages against each other
as well as against the alternative types of cancer immunotherapy. These, along with
prominent examples and recent advances will be discussed in the following sections.
Briefly, the desirable qualities of all immunotherapies are maintained in this
category: precise targeting ability, and diminished side effects versus traditional chemo
and radiotherapy. However, the ability to target tumor-specific or tumor-associated
antigens and epitopes still relies on our ability to identify such proteins. One unique
advantage attributed to anti-cancer vaccines is the ability to provide prophylaxis and to
create long-term immune memory.
Another unique advantage is how easy and fast new vaccines can be designed,
which is particularly useful in the setting of personalized vaccines. This is most useful to
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be able to target neoantigens and neoepitopes, which make ideal targets (since they evade
central tolerance) but are not widely shared by a population of patients and are rather
personalized. With antibody-based strategies and cellular therapy, a new antibody or
antibody fragment needs to be raised against each neoantigen/neoepitope. Here,
synthesizing a new peptide is relatively easier and faster.
Each category of anti-cancer vaccines also suffers from various limitations. Cellbased vaccines are difficult to produce, while sufficient gene delivery remains
challenging, and their stability needs to be further optimized. This category of cancer
immunotherapy, like all others, is also limited by the lack of detectable tumor antigens,
antigen loss and tumor heterogeneity.
The mechanism of action is similar for all three types described in this section.
Cancer vaccines need to induce a strong adaptive immune response to eliminate tumors.
This response begins with the uptake, processing, and MHC-II presentation of the tumor
antigens by DCs. CD4+ T cells can then recognize the presented antigens and activate a
Th1 type response, which includes IFN-gamma secretion that promotes cytotoxic T cell
effector functions. The processed antigen can also undergo cross-presentation, in which
DCs engage CD8+ T cells via MHC-I. Subsequent CD8+ T cell activation requires three
signals: T cell receptor (TCR) binding to peptide presented on MHC-I, co-stimulatory
signaling such as CD28 bound to B7 on DCs, and binding to cytokines such as IL-2 that
promotes T cell expansion. The activated cytotoxic CD8+ can then selectively eliminate
tumor cells that express the cross-presented antigen.
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The following figure further summarizes the described mechanism of action. In
gene vaccines, the antigen is delivered as DNA or mRNA for DCs to express, process
and present. In peptide vaccines, the delivered synthetic sequences of amino acids are
processed and presented by DCs. In cell-based vaccines, the DCs are directly stimulated
ex vivo and administered back to the patient.

Figure 1.7. Cancer vaccine treatment mechanism of action.

1.4.1 Cell-based cancer vaccines
The most widely studied example within this subtype are dendritic cells (DC)
vaccines. The native immune function of these cells is summarized as “professional”
antigen presentation via MHCII, which is why they’re also known as APCs for antigen
presenting cells. Their main function involves surveying endogenous versus exogenous
proteins, followed by presentation of the identified exogenous antigens to naïve T cells to
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induce their activation. DCs act as the bridge between the innate and adaptive immune
systems. They are produced in the bone marrow and circulate throughout the body,
concentrating under the skin and deep within muscle tissue for example. Once they
identify an exogenous antigen, they travel to secondary lymphoid organs to activate T
cells. This process can be hijacked by extracting DCs from patients and pre-activating
them against a known tumor antigen to potentiate their response. They are then reinjected intravenously to allow T cells activation and consequent tumor clearing.
An example in this category is the vaccine Sipuleucel-T, which was approved by
the FDA in 2010 for patients diagnosed with a specific type of prostate cancer
(asymptomatic or minimally symptomatic). It is currently indicated as the highest
recommendation by the National Comprehensive Cancer Network (NCCN) for treating
hormone-refractory prostate cancer (HRPC). Here, patient DCs are incubated with a
fusion protein composed the highly expressed tumor antigen prostatic acid phosphatase
(PAP) and the DC maturation factor granulocyte-macrophage colony stimulating
factor (GM-CSF). Despite its mild overall survival improvement seen in clinical trials
(from 19 to 24 months), Sipuleucel-T has struggled to penetrate its market due to the
aforementioned disadvantages. The challenging manufacturing process is limiting, and
the high complexity leads to a high price that is not easily accepted by insurers.

1.4.2 Gene delivery: DNA and mRNA vaccines
Compared to cell-based vaccines, DNA and mRNA vaccines are easier to produce
and enable facile targeting of multiple tumor antigens simultaneously. However,
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achieving therapeutic immunogenicity remains difficult for multiple reasons. DNA
vaccines need to cross both the cytoplasmic and nuclear membranes. On the other hand,
mRNA vaccines only need to cross the cellular membrane, but are generally hampered by
the lower stability attributed to mRNA versus DNA strands. Recent advances aim to
improve delivery of both types of vaccines as well as the stability of mRNA vaccines.
In this category of anti-tumor vaccines, either a DNA or mRNA copy of a tumor
antigen is supplied as a template for cells to express, in particular for APCs to express.
Here, the genetic material is delivered directly into DC-rich tissue as opposed to ex vivo
as in the previous section. To improve delivery, the templates are encapsulated in cationic
nanoparticles and lipid-based particles, or in a recombinant viral capsule or viral-like
nanoparticle. Encapsulation with chemical nanoparticles is particularly difficult with
mRNA vaccines because they are large negative hydrophilic molecules with secondary
and tertiary structures. The latter bio-based approaches come with their own
disadvantages, such as the immune system rejecting the delivery vector itself and the
added manufacturing complexity (i.e. producing a viral-like nanoparticle is more
complicated versus producing DNA and encapsulating in a nanoparticle).
While we have yet to see an approved genetic vaccine for cancer, the success with
COVID-19 vaccines and many candidates in the clinical pipeline could result in a new
therapy in the coming years. For example, Moderna alone has three candidates in Phase 1
and one in Phase 290. Their personalized lipid-encapsulated cancer vaccine mRNA-4157
targets 34 novel antigens, which are all rarely shared between patients, and was found to
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result in a disease control rate of 90% in head and neck squamous cell carcinoma
(HNSCC) patients91.

1.4.3 Peptide-based vaccines
Theoretically, peptide-based vaccines provide a slight advantage over gene-based
vaccines in they don’t need to penetrate the cellular nucleus (as with DNA vaccines) nor
do they need to be expressed by the cells. Like gene-based vaccines, multiple epitopes
and antigens can be included in peptide-based strategies. With peptide-based vaccines,
there is technically better control over which subtype of T cells (CD4+ vs CD8+) to
engage versus other types of cancer vaccines92.
One main limitation is the poor immunogenicity and limited delivery in vivo.
Challenging antigen selection is the overbearing determinant. The target should ideally be
a neoantigen or neoepitope, as these are not subject to the immune system’s central
tolerance. However, this strategy narrows down the applications to personalized
approaches since most neoantigens and nod broadly present. The peptide selection also
needs to be balanced with the ability to be naturally presented on MHC complexes.
As of 2021, there have been 80+ peptide vaccines for cancer treatment tested in
the clinic, 20 of which are currently active93. Most trials have not advanced past phase II,
highlighting their tolerated safety and the limited therapeutic efficacy that this strategy is
facing.

1.5 ONCOLYTIC VIRUSES
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This class of immunotherapy provides the unique ability to induce tumor-specific
cell lysis and stimulate the immune system like vaccines94. Oncolytic viruses also offer
the added ability to stimulate both the innate and adaptive immune system via viral and
tumor antigens. Generally, its safety profile has been demonstrated to be safe and
tolerable in over 90 clinical trials treating over 3000 patients spanning 2000-202095.
Here, tumor targeting in possible due to the high expression of viral receptors on
the tumor cell surface can be modified to infect cancer cells and cause them to burst. If
we’re able to identify tumor-specific receptors, then viral capsids can also be engineered
to better target those. Second, since tumor cells replicate at a faster rate the average adult
tissue, the viral load is significantly higher at the tumor site, which serves as a call to the
immune system. Tumor cells have also been found to selectively disengage antiviral type
I interferon signaling96. This provides a selection pressure for the virus to selective
replicate at the tumor site. The higher the viral load, the more tumor cell lysis is induced.
Together, the secretion of tumor cellular debris and high viral load have the potential to
overcome immunosuppression at the within the microenvironment.
In 2015 the oncolytic virus Talimogene Laherparepvec (T-Vec) became the first
FDA-approved treatment of its kind for patients with advanced melanoma. This modified
herpes virus secretes GM-CSF to stimulate DCs, which in turn activate tumor-specific
cytotoxic T cells. Clinical data has confirmed its efficacy at the local injection site of
unresectable melanomas, but its systemic effect on metastasis is limited in comparison.
More recently, oncolytic viruses have also been highlighted for the synergy with
immune checkpoints that disrupt PD-1/PD-L1 binding and such97–99. For example, T-Vec
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combined with pembrolizumab led to a response rate of 62%, 33% of which were
complete responses, versus 19.2% with 80% complete in patients treated with just T-Vec.
Another trial also tested T-Vec in combination with ipilimumab versus ipilimumab alone
and found an increased response rate of 38% versus 18%. The success recorded in solid
tumors is mostly attributed to an increase in tumor- infiltrating cytotoxic T cells. The
demonstrated clinical safety and efficacy, as well as its synergy with immune checkpoints
has created interest in the field to further evaluate oncolytic viruses as a treatment for
solid tumors.

1.6 CURRENT CHALLENGES IN CANCER IMMUNOTHERAPY

1.6.1 Identifying therapeutic tumor targets
Our ability to exploit the advantages associated with immunotherapies (high
specificity and less/less severe side effects as opposed to traditional chemo and
radiotherapy) is limited by the identification of targets with an open therapeutic window.
This limitation also hinders all types of immunotherapy. To obtain an adequate
therapeutic window, high tumor-specificity alone is not sufficient; selectivity over
healthy tissues is also required. Poor selectivity typically results in the harmful
autoimmune side effects, such as cytokine release storm, most commonly observed with
bispecific antibody therapy and CAR-T therapy100,101. The commonly targeted antigens in
immunotherapy can be generally placed into two categories: tumor-specific and tumorassociated.
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Tumor-specific antigens (TSA)
These antigens are unique to tumor cells and can either be common to a
population of patients or personalized neoantigens. A third subcategory includes
oncoviral antigens. Tumor-specific antigens possess high specificity, low-to-zero central
tolerance, but are less likely to be common to a large population of patients102.
The majority of neoantigens identified to date are unique to a specific patient’s
tumor103. This poses a complex technical challenge: the process to identify and validate
these neoantigens needs to be completed between the time of diagnosis and the start of
treatment. Despite these technical challenges, this subclass of TSAs is of increasing
interest. In cell-based therapy for example, complete tumor regression has been
correlated to high tumor mutation burden, and neoantigen-specific tumor infiltrating
lymphocytes (TILs) are commonly found in responders104. Additionally, neoantigenspecific circulating TILs have been recorded in various cancer types, including
melanoma, gastrointestinal and ovarian cancers105.
Tumor-associated antigens (TAA)
These antigens are not unique to tumor cells, and include various subcategories as
described by Hollingsworth et al: 1. Cancer/germline antigens, which are usually only
expressed in immune protected tissues such as the testes (example mentioned in this
thesis: NY-ESO-1), 2. Differentiation antigens not normally found on adult tissues
(example mentioned in this thesis: prostatic acid phosphatase (PAP), and 3.
Overexpressed antigens that provide a growth/survival advantage to tumor cells (example
mentioned here: HER2, EGFR)103. They are more commonly shared by a population of
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patients, but their specificity and the central tolerance against them are more variable. Of
note, central tolerance is mostly only important for vaccine strategies, in which immune
clearance by the central and peripheral tolerance mechanism needs to be avoided.
Since this class of antigens is not unique to tumor cells, the risk for on-target, offtumor toxicity is higher. For example, CAR-T therapy designed against colorectal
carcinoembryonic antigen (CEA) resulted in severe colitis for in a significant percentage
of the treated patients since this antigen is also commonly expressed in healthy intestinal
tissue102.

1.6.2 Technologies to identify targets
Antigens for antibody- and cell-based therapies
Long-standing techniques for identifying tumor antigens include sequencing the
DNA of cancer cells and comparing against healthy cells of the same type to identify
genomic differences. The same technique can also be applied using mRNA. These
methods are valid for antibody and cell-based cancer immunotherapies because these two
immunotherapies bypass native immune interactions that are otherwise required by
vaccine therapies.
Serological identification of antigens by recombinant expression
This cloning technique analyzes the anti-tumor humoral response in cancer
patients. It does not require tumor cells to be grown or maintained in vitro, nor does it
rely on T cells recognizing tumor antigens. NY-ESO-1 is an example of a SEREXidentified antigen that has been thoroughly studied106. The steps needed generally
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include: SEREX analysis, database comparison, expression analysis, serology, MHCmotif search for epitopes, ELISPOT T cell reactivity assay, and finally, immunotherapy
application106. For SEREX analysis, first a cDNA library is constructed off a source of
mRNA, which can be either patient-derived tissue or a cell line. This library is then
converted to dsDNA (cDNA) and cloned into bacteriophage. Phage infection of a
bacterial lawn follows. The second step screens for sera or ascites IgG that bind onto the
expressed tumor proteins via anti-human IgG detection. The cDNA can then be
sequenced off the bound phage to identify the tumor antigen targeted by sera IgG. This
process is well described in Figure 1 of Martin et al107.
Phage display for antigen identification
An earlier section of this thesis covered phage display for the identification of
antibodies targeting a known antigen. This strategy can also be reversed by cloning a
cDNA library derived off tumor tissue or tumor cell lines and by screening for phages
that are in turn identified by sera or ascites IgGs. Compared to SEREX, this strategy
eliminates the need for bacterial infection and expression. Another advantage here is that
phage that bind control sera IgG can be removed off the pool before antigen detection to
decrease the rate of false positive hits. Like SEREX, the tumor antigens identified are
limited to those that are extracted in the cDNA library creation, can be expressed by
phage and lack PTMs107.
Protein microarrays
These strategies directly identify antibody-protein binding by immobilizing either
of the two on a solid phase and incubating the second component onto the solid phase.
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Here, again the tumor proteins can be either obtained commercially or purified off tumor
samples. Once a hit is identified, the antigen can be identified by mass spectrometry.
Unlike SEREX and phage display, PTMs are included in this strategy.
Since 2011, protein microarrays have continued to be utilized in oncology as
described by Chen et al108. For example, one study identified a 3-protein signature as
sufficient to determine the invasiveness of pancreatic cancer. Similarly, a set of required
proteins was identified for cancer progression in gastric cancer patients, including
proteins involved in cellular movement and cell trafficking, inflammation and cell
growth. Lastly, in prostate cancer a protein microarray was used to identify decreased
CNDP1 levels, which are associated with more aggressive forms of the disease.
Next-generation sequencing for whole exome sequencing
Recently developed sequencing technologies are changing the way we identify
tumor antigens. For example, next-generation sequencing (NGS) provides better
sensitivity over previously used technologies. The technology is explained in detail by
Illumina on their website as is summarized as follows109. This technology utilizes
adaptors attached to DNA fragments of interest. The adaptors then serve as anchors to
immobilize the various fragments that make up the gene or genes being sequenced (or
whole genome). Bridge amplification allows multiple copies of each fragment to cluster
around the template. This serves to amplify the signal to de read from each fragment.
Once the clusters are formed, the sequence is read by complementary synthesis of
fluorescent amino acids being added one by one. After the addition of each amino acid,
each cluster is read as a fluorescent dot that corresponds to complementary amino acid.
60

The fragment reads are finally aligned to obtain the whole end-to-end sequence of the
desired read.

Figure 1.8. Next generation sequencing workflow.

In the context of antigen identification NGS is used for whole exon sequencing
(WES) of cancer patients versus healthy people. The goal is to identify peptides with
non-synonymous tumor-specific mutations. The selected pool of peptides is narrowed
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down by identifying the most likely to bind on human MHC I complexes (or the patient’s
own in personalized strategies). The selected peptide(s) are then used to pulse DCs ex
vivo and tested for the recognition by the patient’s own T cells110.
Antigens for vaccine therapies
The main difference between these antigens and the ones available for use in
antibody-based therapies is that these must also be able to be recognized by DCs and/or
CTLs. The following sections summarize three different types of strategies as presented
by Leko et al105. The strategies utilized here can also be used to identify antigens for
antibody and cellular-based immunotherapies.
Identifying antigenic peptides targeted by patient-derived anti-tumor CTLs
Anti-tumor CTLs can be derived from a tumor biopsy sample of from the blood of
cancer patients. To figure out the target antigens for these CTLs, a library of tumor
cDNA is transfected into a human cell line, such as HEK-293. The variants are then
sorted for their ability to activate the patient-derived CTL clone. The process is then
repeated with fragments of the identified gene to narrow down the antigenic peptide.
Lastly, the candidate antigenic peptides that contain HLA-binding motifs are sorted for
their ability to induce tumor cell lysis via CTLs. The downside of this method is that it is
laborious and time-consuming, and it prohibits high-throughput screening.
Reverse engineering antigenic peptides within an oncogene or overexpressed gene
“Reverse immunology” involves selecting epitopes within a protein of interest
with adequate HLA-binding motifs. The proteins of interest are selected from known
oncogenes and genes that are selectively overexpressed or aberrantly expressed by
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tumors. HLA binding is sorted in vitro, and the high binders are then used to pulse DCs.
The pulsed DCs are then incubated with CTLs to stimulate T cell activation. Finally,
CTLs clones that are best able to respond to the pulsed DCs are selected and cloned to
identify highly immunogenic peptides.
Eluting antigenic peptides off MHCI molecules on tumor cell surface
This third approach starts by immunoprecipitating MHC I molecules off the
tumor cell surface. The population of antigenic peptides bound onto MHC I is then eluted
off the complexes. The amino acid sequences of the eluted peptides are then determined
via mass spectrometry. This method is particularly useful in identifying required and
associated post translational modifications. However, the sensitivity is still considered
rather low.
The peptide mass profiles can be compared against databases of known proteins
to identify new antigens. This strategy has recently been used to identify noncanonical
antigens, also known as alternative, cryptic or dark-matter antigens. These antigens are
expressed off sequences outside of the canonical protein-coding regions or expressed via
noncanonical processing mechanisms111. One of the advantages of identifying this type of
antigens is that they tend to be both tumor-specific and broadly common in patients as
opposed to canonical antigens which ere one or the other, but rarely both.
There are two main types of MS-driven immunopeptidomic acquisition strategies:
data-driven and data-independent. The former typically produces higher-quality MS
fingerprints, although with lower sensitivity and reproducibility. The latter utilizes all
precursor ions in an unbiased manner to post peptide identification and provides better
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reproducibility across multiple samples. For analysis of the acquired data, multiple
database search algorithms have already been developed, and an increasing number of de
novo sequencing algorithms are also being rapidly reported in the literature111.
Recent advances in this field aim to improve the detection and identification of
HLA-binding peptides. For example, tandem mass tag (TMT) uses barcoded peptides and
exploits an array of isobaric tags to label individual samples. This labeling allows low
abundance peptides to be more readily identified, as well as lower quality MS profiles to
be resolved as summarized by Chong et al.

1.6.3 Tumor heterogeneity and antigen loss
Tumor heterogeneity
Even when a therapeutic antigen is identified and validated, tumor heterogeneity
poses another barrier. This phenomenon is caused by aberrant changes in the tumor
microenvironment, hypoxia, abnormal vascularization, and genetic instability112. Among
all the factors considered, the latter is the most overbearing.
There are three levels to consider when thinking about tumor heterogeneity:
patient-to-patient, intratumorally, and intermetastatic101. Patient-to-patient heterogeneity
is what causes some patients with theoretically identical cancers to respond to certain
treatments while others don’t. This can technically be strategized around, if we’re able to
predict which patients will be responders based on clinical data. However, identifying
responders is not necessarily trivial since the small sample obtained through a biopsy
does not capture the characteristics of all tumor subpopulations. For a given patient, at the
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cellular level, the problem arises when a targeted therapy only eradicates a portion of the
various subpopulations, leaving behind a seed of cells that has an intrinsic advantage and
can grow again leading to refractory disease101. This process can also happen during
metastasis, resulting in intermetastatic heterogeneity.
In addition to the prior existence of an intrinsically advantaged subpopulation
within a population of tumor cells, treatments can cause selection pressure that further
drives the development of resistant subpopulations. Tumors can undergo this process on
their own, as they are constantly and rapidly mutating. However, certain types of
treatments can further exacerbate this process too. Chemotherapy and radiotherapy are
particularly effective at driving mutations that further select resistant subpopulations
because of their DNA-damaging nature and the ability of radiation to induce genomic
instability101. Related to this concept is the following section summarizing the process of
antigen loss.
Antigen loss following targeted immunotherapy
Tumor heterogeneity is also known to feed into a second problem known as tumor
antigen loss. Commonly, targeted therapies against select antigens initially leads to
successful treatment, but this initial clearance is then followed refractory disease that can
no longer be treated in the same targeted manner113. In these cases, the initial treatment
acts a selection pressure for the tumor to eliminate or downregulate the initially targeted
antigen. Out of a heterogenous population of tumor cells, some may exhibit a survival
advantage, which in this case is lesser antigen expression. Under the selection pressure of
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a potent treatment, the advantaged subpopulations prevail. Therefore, the resulting
refractory tumor no longer responds to the same initial treatment.
This concept is also known as tumor escape. The immune system is constantly
hindering or promoting tumor growth, which is known as immunoediting. Immunoediting
can proceed in three ways: elimination (i.e. when your immune system is able to clear out
cancer cells on its own via immunosurveillance), equilibrium, and escape. The inherent
genetic instability of tumor cells and the selection pressure caused by targeted
immunotherapies is what leads to tumor escape.
Two examples of antigen loss are summarized by El-Sayes et al. First, two stage
IV melanoma patients treated with CAR-T therapy were found to express less of the
targeted antigen following treatment. Here, antigen loss was either caused by
downregulation of the target or by selection of antigen-negative subpopulations. Second,
the samples of B-cell acute lymphoblastic leukemia (B-ALL) relapsing patients treated
with anti-CD19 CAR-T were found to have an alternatively spliced CD19 mutation. The
mutant CD19 preserved some functionality while effectively avoiding CAR-T targeting.
An ongoing hypothesis in the field is that by targeting multiple targets, the
selection pressure that leads to tumor antigen loss can be relieved while maintaining
sufficient efficacy. Ruella et al have reported support for this hypothesis in a study that
demonstrated CD19 and CD23 dual targeting to leads to significantly less tumor antigen
loss post treatment versus targeting CD19 alone114.

1.6.4 Strategies to overcome resistance
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As described by El-Sayes, there are three main categories that describe ongoing
strategies to avoid tumor antigen loss and the following treatment resistance.
The first strategy is to combine multiple therapies that are found to be synergistic.
While there are countless examples of combinations that lead to substantial or modest
improvements, the problem with this approach is that it is difficult to rationally design
combinations and nearly impossible to test all possible combinations in the clinic.
Additionally, combination therapy does not necessarily eliminate the risk of therapyinduced antigen loss.
The second strategy involves targeting a broader set of tumor antigens (as
opposed to just one or a few), such as by using peptide-based vaccines which encompass
multiple proteins found on the tumor cell surface. The downside here is that multiple
targets are not always known for a given type of cancer.
Lastly, increasing T cell repertoire against a broader set of antigens can help
reduce the selection pressure that leads to antigen loss. Antigen spread is the process by
which the immune response shifts from targeting one main target to additional secondary
targets, which can include different epitopes from the same primary antigen or additional
antigens. It is known to occur during cell lysis, such as the tumor burst caused by
oncolytic viral treatment. El-Sayes et al cites several examples of observed antigen
spread. The first example relates to melanoma patients treated with autologous DCs
pulsed ex vivo with one immunodominant antigen. In this clinical trial, treatment success
did not corelate to antigen specificity. Most interestingly, the one patient with a complete
response was found to exhibit antigen spread to other melanoma epitopes that were not
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included in the vaccine115. Additionally, antigen spread has been shown to be induced by
radiation therapy in a murine melanoma model116. In this thesis, the use of patient’s own
circulating, endogenous antibodies as the targeting moiety in a bispecific antibody is
hypothesized to alleviate the selection pressure against a single target.
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CHAPTER 2: RAPID, SITE-SPECIFIC LABELING OF ‘OFF-THE-SHELF’ AND
NATIVE SERUM AUTOANTIBODIES WITH T CELL-REDIRECTING
DOMAINS
This work has been adapted from Zappala et al 2022, under review at Science Advances
as of February 2022.
2.1 ABSTRACT
Extensive antibody engineering and cloning is typically required to generate new
bispecific antibodies. Made-to-order genes, advanced expression systems, and high
efficiency cloning can simplify and accelerate this process, but it still can take months
before a functional product is realized. We developed a simple method to site-specifically
and covalently attach a T cell redirecting domain to any off-the-shelf, human
Immunoglobulin G (IgG) or native IgG isolated from serum. No antibody engineering,
cloning or knowledge of the antibody sequence is required. Bispecific antibodies are
generated in just hours. By labeling antibodies isolated from tumor-bearing mice,
including two syngeneic models, we generated T cell-redirecting autoantibodies
(TRAAbs) that act as an effective therapeutic. TRAAbs preferentially bind tumor tissue
over healthy tissue, indicating a significant therapeutic window. The use of
autoantibodies to direct the tumor targeting of bispecific antibodies represents a new
paradigm in personalized medicine that eliminates the need to identify tumor biomarkers.

2.2 INTRODUCTION
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Bispecific antibodies (BiAbs) have emerged as a promising cancer treatment, with
a growing list of encouraging clinical results 45,117. BiAbs enable the binding of two
separate targets or the binding of two distinct sites on the same target, simultaneously.
This can have important implications when applied as a therapeutic, such as improved
specificity and/or unique biological effects 118–121. In one common application, BiAbs are
designed to physically bring T cells and cancer cells closer together to enhance the
immune clearing of cancer cells. Demonstrating the promise of T cell-redirecting BiAbs,
blinatumomab, an anti-CD3 x anti-CD19 pair, has produced clinical remission in
precursor B cell acute lymphoblastic leukemia at thousand-fold lower dosages than
rituximab (anti-CD20 monoclonal antibody), without needing a secondary T cell costimulatory signal 122–124. Similarly, catumaxomab (anti-CD3 x anti-EpCAM) has led to
clinical benefit in patients with malignant ascites at a dose totaling 230 μg over 11 days
118,125–127

. In contrast, conventional antibody therapies require cumulative antibody doses

ranging from 5-20 g per patient over the course of months to years 128.
Many BiAb formats have been developed, but the generation of highly uniform
BiAbs generally requires extensive antibody engineering or cloning up front, due to the
low yields and purity of forming BiAbs by chemical crosslinking techniques 129 and the
limited versatility and applicability of species-restricted pairing (e.g. Triomab) 128,130–132.
Even though made-to-order genes, advanced expression systems and high efficiency
cloning techniques speed up and simplify the creation of BiAbs, it can still take months to
make each new BiAb construct. Issues like loss of specificity, aggregation, light chain
swapping, heterogeneity can further slowdown this process and additional time and
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expertise are required when exact antibody sequences are unknown and must still be
determined. This creates a barrier for entry into this field for many labs and slows down
the productivity of others. A methodology that produces functional BiAbs from off-theshelf Immunglobulin G (IgG) or native antibodies from serum or culture, without the
need for antibody engineering and cloning, could offer unique opportunities to accelerate
bispecific antibody research and enable new therapeutic paradigms.
Here, we describe a simple method to attach an anti-CD3 targeting domain sitespecifically and covalently to the heavy chains of any off-the-shelf, full-length IgG. This
approach to making BiAbs does not require antibody engineering, cloning, or
modifications, thus reducing the BiAb production time from months to hours. Our
technique utilizes a photoreactive antibody-binding domain (pAbBD) that is derived from
the small (~6.5kDa), thermally stable HTB1 domain of a version of Protein G that only
binds to the Fc region of antibodies 133. Our lab has engineered this pAbBD to contain a
photoreactive unnatural amino acid in the Fc-binding site 134. The photoreactive amino
acid within the pAbBD domain creates a covalent link between a pAbBD-anti-CD3
fusion protein and an IgG of interest to prevent dissociation (Fig. 1a). This technique
allows control over the number of modifications per IgG molecule, and results in uniform
antibody conjugates in high yields.
BiAbs were produced from a range of clinically approved IgGs and their
functionalities were examined to demonstrate the method’s ease and utility. Further, we
tested whether a living subject’s endogenous antibodies can be transformed into
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bispecific T cell re-directing autoantibodies (TRAAbs) and used to enhance the immune
system’s ability to specifically suppress and/or eradicate malignant cells.

2.3 RESULTS

2.3.1 Rapid production of BiAbs

Figure 2.9. Rapid bispecific antibody (BiAb) production mediated by a photoreactive antibody-domain (pAbBD)
results in six different, pure constructs that bind their respective tumor targets as expected.
a, An anti-CD3 small chain variable fragment (scFv) was fused with a photoreactive antibody-binding domain
(pAbBD). Two h of irradiation with non-damaging long-wavelength UV light induces covalent attachment of the
fusion protein to the IgG Fc-region. b, Six human antibodies - rituximab, cetuximab, trastuzumab, IgG2, IgG3, and
IgG4 – and the resulting BiAbs produced by photo-crosslinking with pAbBD-anti-CD3 fusion protein were analyzed
on a reducing SDS-PAGE. Unbound, excess pAbBD-scFv was removed via filtration. The bands represent IgG heavy
chains (HC) before and after photo-crosslinking. c-e, HER2+ T617, EGFR+ MDA-MB-468 and CD20+ HT1080 cell
lines were seeded, fixed and blocked with normal goat serum. Binding curves of photo-crosslinked (C) anti-HER2
(trastuzumab) x anti-CD3, (D) anti-EGFR (cetuximab) x anti- CD3, and (E) anti-CD20 (rituximab) x anti-CD3 BiAbs,
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and the respective monospecific antibodies from which they were derived, were obtained after incubation with a
fluorescent secondary antibody. Fluorescence intensity was measured using a plate reader. The Kd values were (A) 0.9
nM for the BiAb and 1.16 nM for monoclonal antibody, (B) 0.60 nM for the BiAb and 0.49 nM for the monoclonal
antibody, and (C) 8.2 nM for the BiAb and 12 nM for the monoclonal antibody. All R2 values are greater than 0.9. f,
Human T cells were incubated with serial dilutions of anti-EGFR x anti-CD3 scFv BiAb, free anti-CD3 scFv, and
positive control OKT3, and binding was measured via flow cytometry. The Kd values were found to be 1.89 nM, 35 nM
and 34 nM for OKT3, CD3 scFv and BiAb with R2 values 0.99, 0.985 and 0.99, respectively.

To enable the rapid functionalization of antibodies, namely IgG, with T cell
redirecting domains, we created fusion proteins composed of photoreactive antibodybinding domains (pAbBDs) and anti-CD3 targeting domains (Figure 2.9a). The pAbBD
was derived from the hyperthermal variant of the Protein G B1 domain (HTB1) and
includes the photoreactive unnatural amino acid, benzoyl phenylalanine (BPA), at the
A24 site 135. This substitution places BPA within close proximity of the CH2-CH3 hinge
on the IgG heavy chain (Fc region) and enables efficient photo-crosslinking to most
species and subclasses of IgG upon exposure to non-damaging, long wavelength
ultraviolet (UV) light (365 nm) 134. The exact conjugation site on IgG is likely
Methionine 252, since the presence of this amino acid was previously found to corelate
with the ability to efficiently photo-crosslink antibodies of various species 134. Two
different anti-CD3 targeting domains were evaluated, a single-chain variable fragment
(scFv) derived from the antibody OKT-3 136 and a CD3-targeted nanobody 137.
BiAbs were prepared by mixing the pAbBD-anti-CD3 fusion proteins with the
desired antibody and then irradiating with 365 nm light for two hours. Six different T cell
redirecting BiAbs were created simultaneously from three FDA-approved IgG1
73

antibodies, cetuximab (anti-EGFR), rituximab (anti-CD20) and trastuzumab (anti-HER2),
and three additional human IgG subclasses, IgG2, IgG3, and IgG4 (Fig. 2.9b and
Supplementary Fig. 2.1a). The photo-crosslinking is nearly 100%, resulting in BiAbs
with two pAbBD-anti-CD3 per IgG (one pAbBD-anti-CD3 per heavy chain). Nonreducing SDS-PAGE and fast liquid protein chromatography (FPLC) traces of cetuximab
before and after photo-crosslinking further confirm nearly 100% conversion. No
substantial higher or lower molecular weight side products were detected (Supplementary
Fig. 2.2). This approach can be further parallelized to create 100s or even thousands of
BiAbs simultaneously, for possible screening applications. As proof-of-principle, we
generated 80 BiAbs in a single photo-crosslinking experiment with each reaction
exhibiting a conversion efficiency between 92% and 98% (Supplementary Fig. 2.3). This
relatively narrow window of variability results in a small fraction of the BiAbs being
modified with one pAbBD-anti-CD3 fragment instead two in the saturated format, which
could yield varying pharmacokinetics in vivo. Although possible with an appropriate size
exclusion column, in this manuscript this minor heterogeneity was not purified out. The
resulting tetravalent BiAbs were easily separated from free excess pAbBD-anti-CD3,
which are much smaller in size, by ultrafiltration spin columns or dialysis, yielding a final
BiAb with a purity greater than 95% and yield greater than 90%.
A notable feature of using pAbBD-anti-CD3 fusion proteins to generate BiAbs is
the short production time compared with existing genetic methods. Following cloning
and transformation, the pAbBD-anti-CD3 fusion proteins are expressed and purified in
less than 3 days. BiAb photo-crosslinking requires just 2 h, and removal of excess fusion
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protein can be completed on the same day. Therefore, the overall procedure requires just
4 days from start-to-finish and just a single day if pAbBD-anti-CD3 fusions proteins have
already been prepared. In comparison, the timeline for creating a new hybridoma and
producing a BiAb is on the order of months.

2.3.2 Evaluation of photo-crosslinked BiAb binding and T cell activation
To demonstrate that the photo-crosslinking of pAbBD-anti-CD3 onto fusion
proteins to IgG does not negatively impact antigen binding, we compared the relative
affinity of BiAbs against the FDA-approved monospecific, monoclonal antibodies from
which they were derived. The relative binding affinity was assessed by incubating the
monospecific antibodies and the BiAb with corresponding HER2+, EGFR+, or CD20+
adherent cell lines. Dose-dependent binding was detected using fluorescent secondary
antibodies (Fig. 2.9c-e and Supplementary Fig. 2.1b). Our results indicate that there is no
statistically significant difference in the relative binding affinity between the BiAbs and
the corresponding unconjugated, monospecific antibodies. These results confirm that the
site-specific, covalent attachment of the pAbBD-anti-CD3 to IgG does not interfere with
antigen binding.
Binding of the BiAbs to CD3 T cells was also assessed by comparing its binding
activity with the full-length anti-CD3 antibody (OKT3) and free anti-CD3 scFv. The
equilibrium-binding curves of BiAbs for CD3 was found to be similar to free anti-CD3
scFv despite its bivalency (Fig. 2.9f). This could be due to physical restrictions that
prevent the simultaneous binding of the two anti-CD3 scFv’s to CD3, in this particular
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BiAb format. OKT3 was also indirectly detected with a fluorescent secondary antibody,
while the free scFv and the BiAb were both directly labeled with a fluorescent dye, which
could also account for shifts in the binding curves 138. Nonetheless, the BiAbs can
activate human T cells and trigger interferon gamma production in a dose-dependent
manner, similar to full-length OKT3 (Supplementary Fig. 2.4).

2.3.3 T cell mediated cytolysis with photo-crosslinked BiAbs

Figure 2.10. BiAb functionality is confirmed by the T cell mediated in vitro cytolysis targeted against HER2,
EGFR, and CD20.
a-c, T cell mediated cytolysis of HER2+ T617, EGFR+ MDA-MB-468 and CD20+ HT1080 cell lines was monitored
for 72 h as a function of BiAb dose using an xCELLigence real-time cell analysis (RTCA) instrument. Increasing
concentrations of anti-HER2 (trastuzumab) x anti-CD3, anti-EGFR (cetuximab) x anti-CD3, and anti-CD20 (rituximab)
x anti-CD3 BiAbs (black circles) were analyzed, as well as mixtures of the respective unconjugated antibodies and antiCD3 scFv (black triangles), and non-targeted BiAbs (black squares). All BiAbs were prepared using a pAbBD-antiCD3 scFv. All assays were performed with human T cells at a 10:1 effector-to-target (E:T) ratio. BiAbs EC50 values
were (A) 0.038 nM, (B) 0.05 nM and (C) 0.007 nM. All R2 values were greater than 0.9. d-e, Kinetics of T cell-
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mediated cytolysis of EGFR+ tumor cells for (D) increasing concentrations of anti-EGFR (cetuximab) x anti-CD3
BiAb or (E) a mixture of anti-EGFR cetuximab and anti-CD3 scFv. All assays were performed with human T cells
using an E:T of 10:1. f, T cell-mediated cytolysis of EGFR+ cells with increasing E:T ratios, 12 h post-treatment with
0.1 nM EGFR-targeted BiAbs produced with pAbBD-anti-CD3 scFv or 0.1 nM cetuximab mixed with 0.2 nM of free
anti-CD3 scFv.

The therapeutic potential of the photo-crosslinked BiAbs was evaluated via in
vitro T cell-mediated cytolysis. Specifically, anti-HER2 (trastuzumab) x anti-CD3, antiEGFR (cetuximab) x anti-CD3, and anti-CD20 (rituximab) x anti-CD3 BiAbs were
incubated with the respective HER2+, EGFR+, or CD20+ cell lines. T cells were added at
an effector-to-target (E:T) ratio of 10:1 and cell lysis was monitored using xCELLigence
real-time cell analysis (RTCA) for 72 hours (Fig. 2.10a-c and Supplementary Fig. 2.5ac). The BiAbs all exhibited dose-dependent cytotoxicity, with efficacies that are similar
to what was previously reported for alternative genetically engineered BiAb formats 139–
141

, although direct comparisons must be made with caution due to the variability among

cell lines and T cell donors 141. Notably, cytolysis was not observed when non-targeted
BiAbs or mixtures of unconjugated monoclonal antibody and anti-CD3 targeting domains
were used. The kinetics of cell killing was rapid, increasing immediately after the
addition of the BiAb and plateauing within 12 h (Fig. 2.10d,e and Supplementary Fig. 2.6
and 2.7a).
Cytolysis of EGFR+ cells was also measured as a function of increasing effectorto-target (E:T) ratio using the anti-EGFR x anti-CD3 BiAb at a dosage of 0.1 or 1 nM
(Fig. 2.10f and Supplementary Fig. 2.7b). Cytolysis was observed with an E:T ratio as
77

low as 1:1, albeit low (<10%), and plateaued at an E:T ratio of 10:1. Mixtures of
unconjugated monoclonal antibodies and anti-CD3 targeting domains only showed
appreciable killing (~20%) when the E:T ratio was increased to 40:1. Similar cytolysis
trends were observed with both the anti-CD3 scFv and the anti-CD3 nanobody. Finally,
we also compared in vitro cytolysis using human T cells from three different donors in
parallel and found minimum differences in the dose-dependent curves against EGFR+
cells at an E:T ratio of 10:1 (Supplementary Fig. 2.7c).

2.3.4 T cell redirecting autoantibodies (TRAAb)
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Figure 2.11. pAbBD-mediated production of T cell recruiting autoantibodies (TRAAbs) creates personalized,
functional targeted therapeutics without needing to identify tumor markers.
a, Autoantibodies extracted from the serum of mice vaccinated with Nalm-6 B cells were converted into T cellredirecting autoantibodies (TRAAbs) via site-specific, covalent photo-crosslinking of the pAbBD-anti-CD3 fusion
protein. The tumor killing capability of the resulting BiAbs were evaluated in vitro and in vivo using immunodeficient
mice engrafted with human T cells. b, Whole tumor vaccination of C57BL/6 immunocompetent mice with CD19+
Nalm-6 B cell leukemia was completed as follows: 2x106 cells were injected i.p. twice a week for two weeks, followed
by two weeks off. This 28-day cycle was repeated twice before collecting the entire blood volume via cardiac puncture.
Blood samples were also collected after the 2nd and 4th weeks. c, Blood samples of vaccinated mice were centrifuged to
extract serum, and autoantibodies (AAbs) were purified using Protein G agarose resin. TRAAbs were produced via
photo-crosslinking with a pAbBD-anti-CD3 nanobody. Heavy chain (HC) and light chain (LC) are shown before and
after photo-crosslinking on a reducing SDS-PAGE. d, Luciferase-expressing CD19+ Nalm-6 B cell leukemia cells were
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incubated with human T cells, using a 5:1 E:T, and cytolysis was analyzed using the Steady-Glo Luciferase Assay
System (Promega) 24 h post-antibody treatment. Treatments included BiAbs that were generated by photo-crosslinking
pAbBD-anti-CD3 nanobodies to (i) autoantibodies (AAbs) extracted from vaccinated C57BL/6 mice (i.e. TRAAbs),
(ii) IgGs extracted from wild-type C57BL/6 mice and (iii) control anti-CD19 IgGs (MAB1794, EMD Millipore). A T
cell only control was also tested. The EC50 values were found to be 0.92 nM for TRAAbs, using AAbs that were
collected 8 weeks after the first Nalm-6 injection (R2 = 0.99), and 0.90 nM for the anti-CD19 x anti-CD3 positive
control (R2 = 0.95).

The unique ability to create highly uniform BiAbs via the site-specific, chemical
modification of native antibodies with pAbBD-anti-CD3, led us to explore the feasibility
of a new therapeutic paradigm that cannot be achieved with genetic engineering
approaches. Specifically, autoantibodies were isolated from tumor bearing mice and were
converted into T cell-redirecting autoantibodies (TRAAbs) by photo-crosslinking with
pAbBD-anti-CD3, before being introduced back into mice as a form of personalized
cancer therapy (Fig. 2.11a). The use of autoantibodies takes advantage of the immune
system’s innate ability to detect tumor-specific targets and circumvents the need to
identify tumor antigens. Moreover, because TRAAbs are derived from a pool of IgGs that
can recognize diverse tumor targets, they have the potential to overcome many of the
shortcomings that plague monoclonal antibody therapy, such as heterogeneity in target
expression within tumors, patient-to-patient variability, and antigen down-regulation.
The potential for TRAAb therapy was initially established using two different
cancer human cell lines, Nalm-6 leukemia cells and MDA-MB-468 breast carcinoma
cells. Autoantibodies were raised against these tumor cells via repeated intraperitoneal
(i.p) administration into immunocompetent C57BL/6J mice (Fig. 2.11b). Blood was
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collected and all IgG were isolated 2-, 4-, and/or 8-weeks after the first administration of
cancer cells. The antibodies that were extracted after 8 weeks of Nalm-6 exposure, which
include tumor-specific autoantibodies, were found to bind Nalm-6 tumor cells with an
affinity of 4.1x10-8 M (Supplementary Fig. 2.8). Control WT IgGs from healthy mice did
not bind Nalm-6 cells at any of the concentrations tested. The collected IgG were then
converted to TRAAbs and evaluated in T cell-mediated cytolysis assays, using the same
cells that were introduced into mice to generate an anti-tumor response. The efficiency of
photo-crosslinking between pAbBD-anti-CD3 and murine autoantibodies was ~50% (Fig.
3c), which is lower than the photo-crosslinking efficiency to human IgG. This is likely
due to the known low crosslinking efficiency between pAbBD and mIgG1 134.
Nonetheless, the TRAAbs led to the potent, dose-dependent cytolysis of both Nalm-6
(Fig. 2.11d) and MDA-MB-468 cells (Supplementary Fig. 2.9), using the respective
TRAAbs. Non-targeted TRAAbs, generated from antibodies isolated from healthy mouse
serum, and mixtures of the unconjugated autoantibodies and anti-CD3 targeting ligands
did not result in any appreciable cytolysis at the doses tested. Not surprisingly, the
therapeutic efficacy of the TRAAbs improved when autoantibodies were collected after
more i.p. administrations of the Nalm-6 cancer cells. In fact, TRAAbs produced from
autoantibodies collected at 8-weeks following the first administration of CD19-positive
Nalm-6 cells exhibited an EC50 of 0.92 nM, which is comparable to the 0.90 nM EC50
of a positive control consisting of an anti-CD19 x anti-CD3 BiAb.
Next, we tested whether TRAAbs could serve as an effective treatment for mice
bearing Nalm-6 tumors. The Nalm-6 cells were engineered to express luciferase so that
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tumor growth could be monitored longitudinally by bioluminescent imaging. All
TRAAbs for this study were produced using pAbBD-anti-CD3 nanobodies, due to their
more reliable and higher expression, compared with pAbBD-anti-CD3 scFv’s, which was
necessary to facilitate the completion of this in vivo study. NSG mice were used in this
study due to the need to use human T cells. A total dose of 0.5 mg/kg TRAAb, distributed
across 3 i.p. injections every other day, led to a statistically significant slowing of tumor
progression and increased survival (100% over 60-day experiment), compared with
untreated mice, mice treated with non-targeted TRAAbs, and mice treated with a mixture
of unconjugated autoantibodies and anti-CD3 (Fig. 2.12 and Supplementary Fig. 2.10a).
The mixture of unconjugated autoantibodies and anti-CD3 did lead to some slowing of
tumor growth and improvement in median survival compared with the other controls, but
the statistically significant difference between this control and the TRAAbs demonstrates
the benefit of a physical link between the autoantibodies and the anti-CD3 targeting
domain. The i.p. injection of TRAAbs into the mice led to no signs of illness, change in
activity, or weight loss (Supplementary Fig. 2.10b).
In a second study, a total dose of 2.5 mg/kg TRAAb was administered i.p. over
the course of 5 consecutive days into mice 4 days post-injection of Nalm-6 tumor cells,
corresponding to a more advanced stage of disease (Supplementary Fig. 2.10c). The
tumors initially regressed, compared with untreated mice and mice treated with nontargeted TRAAbs, but this was followed by tumor recurrence. Nonetheless, there was a
notable and statistically significant slowing of tumor growth and reduction in tumor
burden post-treatment, compared with all controls.
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Figure 2.12. TRAAb therapeutic efficacy is confirmed by in vivo tumor suppression and improved survival. a-d,
Immunodeficient NSG mice were injected with 0.5M Nalm-6 B cell leukemia cells and (A) left untreated, or treated
with 10M human T cells and 0.025 mg/kg of (B) BiAbs produced from IgGs extracted from WT non-vaccinated mice,
(C) mixed AAbs and anti-CD3 nanobody, or (D) TRAAbs. Treatment was evenly distributed along days 1, 3, and 5, as
was 1 mg of background, wild-type polyclonocal murine IgG (BE0093, BioXCell). Tumor growth was tracked twice
per week via luciferase expression and D-luciferin (PerkinElmer) injections using the IVIS Ilumina system. e,
Averaged bioluminescence readings for groups depicted in A-D. n=6 or 7. At day 28, p<0.05 or smaller between
TRAAb and all controls. f, 60-day Survival Kaplan-Meier curves.

2.3.5 Syngeneic TRAAbs: tumor-specific binding and in vitro cytolysis
After demonstrating that autoantibodies raised against human tumor cell lines in
mice could be converted into TRAAbs and elicit a potent cytolytic effect, we next tested
whether TRAAbs generated from endogenous, circulating antibodies in a syngeneic
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murine cancer model (Figure 2.13a) could also produce similar cytolytic effects. First, we
tested the binding affinity of IgGs extracted from the serum of mice growing CT26
colorectal tumors, 4T1 triple negative breast tumors, and RENCA renal cortical tumors
(Fig. 2.13b and Supplementary Fig. 2.11). In all three models a therapeutic window was
observed between the IgGs extracted from tumor bearing mice versus control IgGs from
healthy mice. The KD values of the circulating IgGs were found to be 6.4x10-8 M, 2. x10-8
M, and 1.3x10-8 M in the CT26, 4T1 and RENCA models, respectively.
The functionality of the syngeneic TRAAbs was assessed via T cell mediated
cytolysis of CT26 and 4T1 cells with the corresponding TRAAbs (Fig. 2.13c and
Supplementary Fig. 2.12). Again, dose-dependent cytolysis with TRAAbs was observed
using an E:T ratio of 8:1 in both models, while the non-targeted control BiAb composed
of WT BALB/c IgGs photo-crosslinked with pAbBD-anti-CD3 resulted in minimal
cytolysis. Importantly, the cytolysis results presented for syngeneic TRAAbs are
representative of about half of the experiments performed. In the other half of the
experiments, neither the TRAAbs nor the positive control yielded any cytolysis and thus
were excluded from the analysis. This is notable since this high level of variability was
not observed in prior studies; however, we believe it most likely stems from differences
in the activity of the freshly extracted T cells being used in each time.
Even though the binding affinities of the autoantibodies extracted from the syngeneic models
were similar to that of the Nalm-6 autoantibodies, the potency of the syngeneic TRAAbs was
significantly lower. This could be due to differences in the percent of tumor-binding
autoantibodies within the pool of IgG collected. The Nalm-6 suspension cells may also be
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inherently more sensitive to T cell-mediated cytolysis in comparison to the syngeneic models,
which are all solid tumors (renal and breast).

Overall, these findings further demonstrate the cytolytic potential of TRAAbs
collected from two syngeneic models, one of which has no pre-identified druggable
targets.

Figure 2.13. Functionality of TRAAbs produced using syngeneic, endogenous antibodies. a, Endogenous
antibodies were extracted from the sera of BALB/c mice growing syngeneic CT26 colorectal tumors subcutaneously, as
well as WT BALB/c mice. The purified IgG were photo-crosslinked with pAbBD-anti-CD3, to create TRAAbs, and
run on a denaturing and native SDS-PAGE. b, Endogenous IgGs from mice with CT26 tumors (Autoantibodies, AAbs)
bind CT26 cells specifically, while no significant binding was observed with control WT IgGs from healthy BALB/c
mice and non-targeted anti-human EGFR (Cetuximab). c, TRAAbs produced using IgGs from CT26 tumor-bearing
mice yielded dose-dependent tumor cytolysis 24 h post-treatment, as does a positive control targeted against mouse
EGFR. A negative control composed of T-cell recruiting WT IgGs led to minimal cytolysis and only at the highest
concentration tested. All syngeneic in vitro studies were completed using an E:T ratio of 8:1.

2.3.6 Binding of endogenous antibodies to tumors versus healthy tissues in syngeneic
models
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To further explore the therapeutic window of TRAAbs, we evaluated their ability
to distinguish between tumor versus healthy tissue. To assess whether endogenous,
circulating antibodies preferentially bind to tumor tissue, the tumor, heart, liver, spleen,
kidney and lungs of BALB/c mice bearing 4T1 and CT26 tumors were harvested and
stained with endogenous IgG (Figure 2.14a,c,d,e). In both models the signal detected in
the tumor was significantly higher than that of the healthy tissues, indicating a therapeutic
window. Our results in the 4T1 model match the trend previously reported132. To further
confirm our results, the CT26-HER cell line was also used, and the signal using a murine
anti-human HER2/neu positive control was found to be significantly higher in the tumor
versus all the other healthy tissues lacking human HER2/neu (Figure 2.14b). While these
results do not entirely eliminate the possibility of T cell redirection towards healthy tissues
against which autoantibodies might be produced, they indicate a possible therapeutic window for
safe therapy.
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Figure 2.14. Circulating endogenous antibodies preferentially target tumor tissue over healthy tissues in two
syngeneic models. a, Immunofluorescent staining of syngeneic colorectal CT26 tumor tissue and healthy tissue of
major organs where endogenous antibodies isolated from CT26 tumor-bearing mice were used as the primary antibody.
The fluorescent signal was quantified and normalized to controls using isotype control secondary antibodies, n=5,
p<0.001 or smaller. b, Replicate of a using positive control cell line CT26-HER2 that was engineered to express human
HER2/neu receptor. Here, staining was done using murine anti-human HER2/neu as a primary antibody. n=3, p<0.01.
c, replicates of a in triple negative breast cancer 4T1 model. n=5, p<0.01. d-e, representative images used for above
quantifications of CT26 and 4T1 circulating antibodies bound on tumor tissues versus healthy tissues of major organs.

2.3.7 Preparation of TRAAbs from human antibodies
While significant hurdles would need to be overcome before TRAAbs could be
considered for human therapeutic use, we believe the approach is conceptually feasible.
As an initial demonstration of feasibility, TRAAbs were produced using IgGs derived
from the serum of two liver cancer patients. The crosslinking efficiency of the pAbBD87

anti-CD3 fusion protein to the heavy chains was ~75% (Supplementary Fig. 2.13). The
IgG extraction yield averaged around 1.4 mg per mL of blood. Following clinical
standards that allow 2.5% blood volume to be drawn at once would allow collection of
~150 mL blood for a patient weighing 75 kg, yielding at least 210 mg IgG. This would
allow for a maximum achievable dose of 2.8 mg of TRAAbs per kg, which surpasses the
doses used in this paper (0.5 and 2.5 mg/kg). The concentration of circulating IgGs in
human serum is around 10 mg per mL; with further development of the IgG extraction
protocol, the maximum achievable dose could increase by another factor of 10.

2.4 DISCUSSION
This work outlines and validates a rapid and efficient method for producing
BiAbs via the site-specific modification of ‘off-the-shelf’ and endogenous serum
autoantibodies with T cell redirecting domains. IgGs are covalently labeled in a sitespecific manner using photoreactive antibody binding domains (pAbBDs). pAbBDs are
derived from the HTB1 domain of the naturally occurring bacterial Protein G 133, which
binds to the IgG Fc region with nanomolar affinity 134, resulting in a maximum of two
pAbBDs crosslinked onto each IgG. Once bound, UV exposure drives covalent
crosslinking via the incorporated unnatural amino acid BPA within the pAbBD. The
entire process requires just 2 steps, mix and illuminate, and is completed in just 2 hours.
Subsequent purification by ultrafiltration or dialysis can result in >95% purity and >90%
yield owing to the high photo-crosslinking efficiency and the large size difference
between the BiAb and the pAbBD-anti-CD3.
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To demonstrate the versatility and robustness of this approach, six different T cell
recruiting BiAbs were produced in parallel by labeling three FDA-approved IgG1
antibodies (cetuximab, trastuzumab, and rituximab), and three human IgG subclasses
(IgG2, IgG3, and IgG4) with an anti-CD3 targeting domain. Two different anti-CD3
targeting domains were tested, an scFv derived from the antibody OKT3 and a nanobody.
The resulting BiAbs were able to bind both the tumor antigen and the CD3 receptor with
the same affinities as the individual components and induce targeted in vitro tumor
cytolysis in a dose-dependent manner. Together, the binding affinity and the T cellmediated cytolysis results show that pAbBD-mediated BiAb production yields functional
therapeutic constructs.
Importantly, the pAbBD can label nearly all IgGs, including IgGs from diverse
species and their subclasses 134,142,143, suggesting that its use in BiAb production can be
applied to virtually any candidate antibody of interest. Moreover, crosslinking is highly
reproducible and can be parallelized, which was demonstrated with the simultaneous
photo-crosslinking of 80 IgGs with pAbBD-anti-CD3 in parallel, with nearly 100%
conversion efficiency for every sample. Bispecific production can likely be further scaled
up to assess 100s or 1000s of antibodies at once using multiple 96-well plates. This
higher throughput BiAb production could be valuable in validating targets and
identifying favorable epitopes and/or synergistic binding partners. Of course, to realize
the full potential of this capability, future work needs to investigate whether BiAbs
produced with pAbBDs can accurately predict the relative efficacy of alternative BiAb
formats that might be more favorable for clinical translation. While it has previously been
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shown that different BiAb formats can display large differences in efficacy 144, it is not
clear whether the correlation between efficacy and specific antibody pairs is maintained
across diverse platforms. Nonetheless, it should be noted that the BiAb presented here is
highly similar in structure to BiAbs with scFv’s fused to the c-terminus of the heavy
chain (e.g Sanofi/SAR156597, Merrimack/MM141, and Aptevo/Mor209/ES414) and
thus is more likely to be predictive of at least this platform.
Perhaps the most valuable attribute of using pAbBDs to create BiAbs is the ability
to rapidly explore unique and complex therapeutic constructs. For example, the anti-CD3
binding portion can be replaced with other protein cargos, such as alternative cellular
recruiting elements, e.g. for NK cells 145, or tested in combination with chemical
moieties, such as drugs or imaging agents 32. Chemical moieties can easily be attached to
the pAbBD-anti-CD3 (or other fusion construct), via enzyme mediated ligation 147,148. In
addition, multiple targeting domains can be fused to pAbBDs in tandem, either against
the same target or different targets, to create higher affinity or multi-specific constructs.
Engineering of pAbBDs is simple, compared with full-length antibody- and antibody
fragment-fusion proteins, due to the pAbBD’s small size, highly stable structure, lack of
disulfides, and high expression levels as soluble proteins in E. coli.
To highlight how pAbBDs can be used to explore unique therapeutic approaches
that cannot be pursued with conventional genetically engineered BiAbs, we generated T
cell recruiting autoantibodies (TRAAbs). Here, we were interested in testing whether
endogenous, circulating antibodies could be used as the targeting unit in T cell redirecting
BiAbs. The unique specificity of endogenous, tumor-associated autoantibodies that are
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found in circulation in the serum of cancer patients have led them to be widely evaluated
as biomarkers, prognostic factors, and indicators of tumor recurrence 62,65,75,80,83,147–154.
By converting autoantibodies into TRAAbs, we harnessed this unique specificity, while
also taking advantage of the potent therapeutic effect provided by T cell recruitment.
Here, autoantibodies extracted from the serum of mice vaccinated with human B cell
leukemia cells were labeled with pAbBD-anti-CD3. TRAAb functionality was
demonstrated via dose-dependent cytolysis of four different cancer cell lines in vitro and
tumor regression and improved survival in vivo. Importantly, two of the tumor models
used to generate TRAAbs were syngeneic, one of them being a triple negative breast
cancer model for which there are currently no clinically validated targets. Further, the
extracted endogenous IgGs of both syngeneic models were found to preferentially bind
tumor tissue versus healthy tissue of major organs, indicating a significant therapeutic
window.
Many questions still need to be answered before TRAAbs can be considered for
clinical use. First, the potency of the humoral response as a function of time would need
to be further elucidated. In the Nalm-6 studies, we found that the potency of TRAAbs
increased with the number of immunizations. The relationship between humoral response
and clinical stage requires further investigation and is likely to dictate how and when
TRAAbs can be offered as a therapeutic option. Second, the pAbBDs utilized here are
bacterial in origin, which could limit their clinical utility. However, it should be noted
that therapeutic proteins derived from other bacterial antibody-binding domains have
already been tested in multiple different clinical trials and have been fund found to be
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safe 28–30,155. Alternatively, it is conceivable that analogous pAbBDs could be derived
from human proteins that exhibit a high affinity for IgG 156,157. Third, since pAbBDs bind
to the same region of IgG as the neonatal Fc Receptor (FcRn), it could negatively impact
the circulation half-life of TRAAbs. One possible solution may be to utilize a 1:1 pAbBD
to IgG molar ratio, which would free up one Fc site for FcRn binding. Fourth, even
though TRAAbs are likely to possess a therapeutic window, it is well known that
endogenous autoantibodies can also bind healthy tissues and therefore may still elicit an
off-target effect 158–160. Further studies are required to assess such dose-dependent
toxicities. One possible approach to alleviate these concerns would be to identify a
method that could allow for the separation of anti-tumor antibodies from other
endogenous antibodies. Finally, the production method presented here utilizes UV photocrosslinking to drive the formation of BiAbs. The question of how this would scale up
remains open ended, as with any new manufacturing method. Despite these unknowns,
we believe that TRAAbs represent a new paradigm in cancer immunotherapy. Our data
points to the possibility of a cellular recruiting treatment that can circumvent antigen
identification and overcome patient-to-patient variability and tumor heterogeneity.
Further, by targeting a broad pool of tumor antigens, TRAAb therapy could remove the
selection pressure that is associated with targeted immunotherapies and is believed to
drive antigen loss and tumor recurrence.
In summary, we believe that pAbBD-mediated BiAb production will serve as a
robust tool for research and development of new antibody-based immunotherapies,
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including personalized strategies that utilize the immune system’s innate ability to
recognize tumor targets.

2.5 SUPPLEMENTARY INFORMATION

2.5.1 Supplementary Tables
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Supplementary Table 2.1. DNA and protein sequences of constructs used in this study.
Construct
pAbBD

Protein Sequence

DNA Sequence

MTFKLIINGKTLKGEITIEAVDA

ATGACCTTTAAACTGATTATTAACGGCAAAACC

*EAEKIFKQYANDYGIDGEWT

CTGAAAGGCGAAATTACCATTGAAGCGGTGGA

YDDATKTFTVTE

TGCGTAGGAAGCGGAAAAAATTTTTAAACAGT
ATGCGAACGATTATGGCATTGATGGCGAATGG
ACCTATGATGATGCGACCAAAACCTTTACCGTG
ACCGAA

anti-CD3 scFv

MDIKLQQSGAELARPGASVKM

ATGGATATAAAACTGCAGCAATCTGGAGCTGA

SCKTSGYTFTRYTMHWVKQRP

ACTGGCACGTCCAGGTGCAAGTGTTAAGATGT

GQGLEWIGYINPSRGYTNYNQ

CTTGTAAAACTTCCGGCTACACTTTTACCAGGT

KFKDKATLTTDKSSSTAYMQL

ACACAATGCATTGGGTAAAACAAAGACCAGGT

SSLTSEDSAVYYCARYYDDHY

CAAGGTTTGGAATGGATAGGTTATATCAATCCC

CLDYWGQGTTLTVSSVEGGSG

AGCAGAGGTTATACTAACTACAACCAAAAGTT

GSGGSGGSGGVDDIQLTQSPAI

CAAAGATAAAGCGACACTAACAACCGATAAAT

MSASPGEKVTMTCRASSSVSY

CTTCTTCCACAGCATACATGCAGTTATCTAGTT

MNWYQQKSGTSPKRWIYDTS

TGACCAGTGAAGACTCAGCTGTGTATTACTGTG

KVASGVPYRFSGSGSGTSYSLT

CTAGGTACTACGATGATCATTATTGTTTAGATT

ISSMEAEDAATYYCQQWSSNP

ATTGGGGACAGGGGACAACTCTTACAGTTAGC

LTFGAGTKLELKLE

TCTGTCGAGGGTGGATCTGGGGGGTCCGGTGG
TTCAGGGGGTTCTGGAGGTGTTGACGATATTCA
GCTAACCCAATCACCAGCCATAATGTCAGCCTC
TCCAGGCGAAAAAGTTACGATGACTTGTAGAG
CATCTAGTTCCGTGAGTTATATGAACTGGTACC
AACAGAAGTCAGGCACTTCTCCAAAGAGATGG
ATCTACGACACTTCTAAAGTCGCTAGTGGTGTG
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CCGTATAGATTCAGTGGATCAGGTTCTGGTACC
TCTTACTCACTGACTATTTCATCTATGGAAGCT
GAAGATGCCGCAACGTACTATTGTCAACAATG
GTCTTCAAATCCATTGACCTTCGGTGCAGGTAC
TAAGTTAGAATTAAAACTCGAG
anti-CD3

EVQLVESGGGPVQAGGSLRLS

GAAGTCCAGTTAGTAGAGAGCGGGGGTGGTCC

nanobody

CAASGRTYRGYSMGWFRQAP

AGTACAAGCTGGAGGCAGCCTTCGTTTATCGTG

GKEREFVAAIVWSGGNTYYED

TGCCGCAAGTGGTCGTACTTATCGTGGTTACAG

SVKGRFTISRDNAKNTMYLQM

TATGGGGTGGTTTCGCCAAGCCCCCGGGAAGG

TSLKPEDSATYYCAAKIRPYIF

AGCGTGAGTTTGTGGCCGCAATCGTTTGGAGTG

KIAGQYDYWGQGTQVTVSS

GTGGCAACACATACTACGAGGATTCAGTCAAG
GGACGCTTTACAATTTCTCGTGATAATGCAAAA
AACACGATGTATCTGCAAATGACATCTCTGAA
GCCGGAGGACAGTGCCACGTATTATTGCGCCG
CTAAAATTCGCCCCTATATCTTCAAGATTGCAG
GGCAATACGATTATTGGGGTCAGGGCACTCAA
GTCACCGTTTCATCG
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2.5.2 Supplementary Figures

Supplementary Figure 2.1. pAbBD-mediated production of BiAbs is compatible with a second anti-CD3 format
and, as with the first format, the binding affinity of the parental IgG is not compromised.
a, Six human antibodies - Rituximab, Cetuximab, Trastuzumab, IgG2, IgG3, and IgG4 – were modified with a pAbBDanti-CD3 nanobody to create BiAbs. The resulting BiAbs and the monospecific antibodies from which they were
derived were run on a reducing SDS-PAGE. The bands represent IgG heavy chains (HC) before and after photocrosslinking. b, EGFR+ MDA-MB-468 breast cancer cells were seeded, fixed and blocked before incubating with serial
dilutions of BiAbs. The BiAbs were produced by modifying Cetuximab with pAbBD-anti-CD3 nanobodies. Binding
was measured via fluorescent secondary antibodies and quantified using a plate reader. The Kd values were found to be
0.23 nM for the BiAb and 0.24 nM for the monospecific control. The R2 values were found to be 0.96 and 0.98,
respectively.
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Supplementary Figure 2.2. Non-reducing SDS-PAGE and fast protein liquid chromatography (FPLC) trace of
Cetuximab before and after photo-crosslinking.
a. Reducing and non-reducing SDS-PAGE of Cetuximab before and after photo-crosslinking with pAbBDanti-CD3 nanobodies. Nearly 90% conversion of the heavy chains is estimated using ImageJ. b-e. Size exclusion
chromatography (SEC) raw trace of b. Cetuximab, c. pAbBD-anti-CD3 nanobody, d. Cetuximab x anti-CD3, and e.
standards.
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Supplementary Figure 2.3. SDS-PAGE of 80 BiAbs produced simultaneously using pAbBDs.
Four different alternating antibodies, including human IgG, Cetuximab, Rituximab and Trastuzumab were aliquoted
into 80 separate wells and photo-crosslinked with pAbBD-anti-CD3 in parallel. In each well, 1 µg of antibody was
mixed with excess pAbBD-aCD3 nanobody, and exposed under 365nm UV light for 2hrs. The products were imaged
on a reducing SDS-PAGE. Nearly all of the heavy chains were covalently modified with the pAbBD fusion protein.
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Supplementary Figure 2.4. BiAbs functionality is further confirmed by dose-dependent T cell activation
measured via IFN-gamma release.
a, 1x106 human T cells were incubated overnight with 1, 10, and 100 nM BiAbs made with aCD3 scFv and three
different antibodies, as well as with free anti-CD3 scFv and OKT3. T cell activation was assessed via interferongamma release into the supernatant and quantified using a commercial interferon-gamma ELISA kit (Biolegend). b,
Replicate of a, using aCD3 nanobody on its own and crosslinked to mouse IgG or Cetuximab.

Supplementary Figure 2 5. BiAbs produced with pAbBD-anti-CD3nanobody induce T cell mediated in vitro
cytolysis targeted against HER2, EGFR, and CD20.
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a-c, T cell mediated cytolysis of HER2+ T617, EGFR+ MDA-MB-468 and CD20+ HT1080 cell lines was monitored
for 72 h as a function of BiAb dose using an xCELLigence real-time cell analysis (RTCA) instrument. E:T ratio was
kept constant at 10:1. Here, all BiAbs were prepared using a pAbBD-anti-CD3 nanobody. Increasing concentrations of
anti-HER2 (trastuzumab) x anti-CD3, anti-EGFR (cetuximab) x anti-CD3, and anti-CD20 (rituximab) x anti-CD3
BiAbs (black circles) were analyzed, as well as mixtures of the respective unconjugated antibodies and anti-CD3
nanobody (black triangles), and non-targeted BiAbs (black squares). The EC50 values for the BiAbs were found to be a,
0.41 nM b, 0.67 nM and c, 35.2 nM. All R2 values were greater than 0.90.

Supplementary Figure 2.6. T cell mediated in vitro cytolysis kinetics for BiAbs produced with pAbBD-antiCD3scFv.
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Kinetics of T cell mediated cytolysis of HER2+ and CD20+ tumor cells with various doses of HER2- or CD20-targeted
BiAbs produced with a pAbBD-anti-CD3 scFv. Cells were treated with increasing concentrations of a, anti-HER2 x
anti-CD3 BiAb b, anti-CD20 x anti-CD3 BiAb c, mixtures of anti-HER2 antibodies and anti-CD3 scFvs and d,
mixtures of anti-CD20 antibodies and anti-CD3 scFvs. All assays were performed using a 10:1 E:T ratio. Cytolysis was
monitored using an xCELLigence real-time cell analysis (RTCA) instrument.
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Supplementary Figure 2.7. T cell mediated in vitro cytolysis kinetics and T cell-mediated cytolysis of EGFR+
cells with increasing E:T ratios for BiAb produced with pAbBD-anti-CD3nanobody.
a, Kinetics of T cell-mediated cytolysis of EGFR+ cells with various doses of EGFR-targeted BiAbs. All BiABs were
produced with a pAbBD-anti-CD3 nanobody. All assays were performed using a 10:1 E:T ratio. b, T cell-mediated
cytolysis of EGFR+ cells with increasing E:T ratios, 12 h post-treatment. Cells were treated with 1 nM EGFR-targeted
BiAbs, produced with a pAbBD-anti-CD3 nanobody, or 1 nM Cetuximab mixed with 2 nM of free anti-CD3 nanobody.
c, Additional replicates of a dose-response cytolysis study using anti-EGFR BiAbs with T cells expanded from three
different healthy donors (E:T ratio = 10:1 ; 72 hours).

Supplementary Figure 2.8. Binding of autoantibodies extracted from the sera of immunocompetent C57BL/6
mice exposed to NALM-6 tumor cells for 8 weeks versus WT control IgGs extracted from healthy mice.
Binding was detected using a PE-labeled anti-mouse IgG secondary and flow cytometry. Briefly, 1x105 cells were
blocked with normal goat serum, followed by human FcR blocker. Primary autoantibodies were incubated at room
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temperature 30 min, followed by 1:200 secondary antibody incubation 30 min at room temperature. The binding
affinity of autoantibodies against NALM-6 was found to be 4.1x10-8 M.

Supplementary Figure 2.9. TRAAbs against MDA-MB-468 produced with pAbBD-anti-CD3scFv induce in vitro
tumor-targeted cytolysis.
TRAAbs were produced following vaccination of immunocompetent mice with EGFR+ MDA-MB-468 breast tumor
cells. All TRAAbs were produced by photo-crosslinking the extracted autoantibodies with a pAbBD-anti-CD3 scFv. T
cell-mediated cytolysis of MDA-MB-468 cells was assessed in vitro following treatment with (i) TRAAbs (black
circle), (ii) mixed autoantibodies and anti-CD3 scFv (black triangles), or (iii) TRAAbs prepared using autoantibodies
from wild-type mice (black squares). All studies were performed in the presence of human T cells at an E:T of 10:1. T
cell mediated cytolysis was monitored using an xCELLigence real-time cell analysis (RTCA) instrument for 72 h as a
function of dose. EC50 values are 0.14 nM, 117 nM and 590 nM for TRAAB, a mixture of unconjugated antibody and
anti-CD3 scFv, and non-targeted BiAb, respectively. All curves had R2 values greater than 0.9.
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Supplementary Figure 2.10. Representative bioluminescent images of in vivo TRAAb treatment and tracked
mouse body weights.
a, Representative bioluminescence images of mice bearing Nalm-6 tumors 1, 15, and 28 days following the
administration of BiAbs produced with control wildtype mouse IgGs, TRAAbs, or AAbs mixed with anti-CD3
nanobodies. Untreated mice were also monitored. Mice were injected with 150μl of filtered D-Luciferin at 15 mg/mL
and the images with peak luminescence were chosen at each timepoint. b, Averaged mouse weights following the
treatments indicated. c, NALM-6 tumor cells (1x106 cells) were injected i.v. into NSG mice. After 4 days, mice were
treated with a total dose of 2.5 mg/kg TRAAbs. In vivo tumor burden was lessened with TRAAbs compared with
control IgG x anti-CD3 BsAbs (n=3; at day 16 p<0.000001).
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Supplementary Figure 2.11. Dose-dependent, tumor-specific binding of circulating endogenous autoantibodies
(AAbs) extracted from syngeneic tumor-bearing mice.
IgGs were extracted from BALB/c mice growing syngeneic tumors (upward triangles) a, 4T1 triple negative breast
cancer and b, RENCA renal adenocarcinoma. In both models, IgGs extracted from mice with tumors show significantly
higher affinity for the corresponding tumor cells compared with IgGs extracted from healthy mice (squares). Nontargeted negative controls exhibited minimal binding (empty circles).
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Supplementary Figure 2.12. Cytolysis of syngeneic tumor cells using TRAAbs.
a, Kinetics of CT26 cell cytolysis following treatment with 33 nM TRAAbs. The TRAAbs were produced from IgGs
extracted from mice bearing syngeneic CT26 tumors. Anti-EGFR x anti-CD3 BiAbs were used as a positive, and
control WT IgG x anti-CD3 BiAbs were used as a negative control. b, In vitro T-cell mediated cytolysis assay of 4T1
triple negative breast cancer cells using TRAAbs. The TRAAbs were produced from IgGs extracted from mice bearing
syngeneic 4T1 tumors. IgG x anti-CD3 BiAbs were used as a negative control. c, Corresponding kinetic curves for 4T1
cytolysis at 100 nM TRAAbs or IgG x anti-CD3 BiAbs. All syngeneic in vitro studies used an E:T ratio of 8:1.
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Supplementary Figure 2.13. IgGs were extracted from the sera of two human liver cancer patients and modified
with pAbBD-anti-CD3 nanobody.
a, Reducing SDS-PAGE shows a shift to modified heavy chains in ~75% of the total IgG heavy chains. b, IgG
extraction yields were found to be 1.8 and 1.0 mg per mL of blood.

107

2.6 METHODS

2.6.1 Cloning
To prepare bispecific antibodies, a photoreactive antibody-binding domain with
BPA introduced at the A24 site146 was fused with an anti-CD3 scFv derived from fulllength OKT3 antibody138 or with an anti-CD3 nanobody141. For the pAbBD-anti-CD3
scFv fusion protein, the DNA coding sequences were inserted into a NdeI and XhoIdigested PBSL vector138,146. For the pAbBD-anti-CD3 nanobody fusion protein, the DNA
coding sequence was first cloned in frame with our STEPL expression system134 and then
inserted into a NdeI and BamHI-digested pmjs187 vector, which was kindly provided by
Dr. Lloyd Ruddock (University of Oulu). A second plasmid was cloned to include an
additional copy of the anti-CD3 nanobody in addition to pAbBD-anti-CD3 nanobody. For
both scFv and nanobody formats, a control construct was also cloned without pAbBD.
All synthesized DNA sequences were codon optimized for E. coli. expression and
produced by Integrated DNA Technologies. Synthesized DNA sequences were inserted
into vectors that were double-digested with the aforementioned restriction enzymes and
cloned using In-Fusion HD Cloning (Clontech). Cloning was verified by Sanger
sequencing. Protein and DNA sequences for all purified proteins are listed in Table S1.

2.6.2 Protein Expression and Characterization
Origami B(DE3) Competent Cells (EMD Millipore) were co-transformed with the
pAbBD-anti-CD3 scFv plasmid and the pEVOL-pBpF plasmid (Addgene plasmid
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#31190), which carries the tRNA/aminoacyl transferase pair152. T7 Express Competent
Cells (Invitrogen) were co-transformed with pEVOL-pBpF and the pAbBD-anti-CD3
nanobody fusion as well as the version containing a second copy of the anti-CD3
nanobody. The anti-CD3 scFv and nanobody without pAbBD were also transformed into
T7 Express and Origami B(DE3), respectively.
Bacterial starter cultures were grown overnight at 37°C in a shaker in 2 mL LB +
100µg/mL ampicillin + 25 µg/mL chloramphenicol. Starter cultures were added at a
1:1000 dilution to Autoinduction Media LB Broth Base Including Trace Elements
(Formedium) with 100µg/mL ampicillin and 25 µg/mL chloramphenicol. For BPA
incorporation, L-benzoylphenylalanine (Bachem, King of Prussia, PA) was added into
the media to a final concentration of 500 μM and arabinose was added to a final
concentration of 0.1% to induce the pEVOL promoter. The pAbBD-anti-CD3 scFv and
the free scFv were expressed in a 25°C shaker for 72 hrs, while the pAbBD-anti-CD3
nanobody and the free nanobody were expressed in a 37°C shaker for 24 hrs. The
pAbBD-anti-CD3-anti-CD3 version containing two nanobodies was expressed at 25°C
for 48 hrs.
After bacterial recombinant expression of the pAbBD-anti-CD3 proteins, cultures
were pelleted by centrifugation (5,500 g for 15 min at 4°C) and purified as previously
described153. SDS-PAGE electrophoresis was performed on Bolt 4-12% Bis-Tris Plus
Gels (Thermo Fisher Scientific) with a Mini Gel Tank (Thermo Fisher Scientific), stained
with SimplyBlue SafeStain (Invitrogen), and imaged using a Gel Logic 100 system
(Kodak).
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2.6.3 Photo-crosslinking of pAbBD-CD3 fusion proteins onto IgGs
To create T cell redirecting BiAbs and TRAAbs, the purified recombinant
pAbBD-CD3 fusion proteins were mixed with the IgG of choice (cetuximab, rituximab,
trastuzumab, or endogenous antibodies) using a slight excess of at least 2.5:1 molar ratio
and exposed to long wavelength UV light (365nm) for 2 hrs160. The photo-crosslinked
IgGs were purified by removing excess pAbBD-anti-CD3 using 100 kDa molecular
weight cut-off (MWCO) filters (Amicon Ultra, Milipore, Temecula, CA) or dialyzing
into sterile PBS using a cellulose ester (CE) membrane (Spectra/Por). Final sample purity
and concentration were assessed by reducing SDS-PAGE comparing against known
amounts of IgG. Conversion efficiency of the heavy chains was estimated via the gel
band intensity using ImageJ.
To further characterize the photo-crosslinking reaction, fast protein liquid
chromatography was performed using an Akta Pure and a Superdex 200 Increase 10/300
GL size exclusion column. The flow rate used was 0.5 mL/min, and the standards used
were BioRad gel filtration standards (Catalog# 1511901).

2.6.4 Binding affinity assays
The relative binding affinity of BiAbs versus the corresponding unconjugated
monoclonal antibodies were assessed using HER+ T617 cells (kindly provided by
Professor Mark Greene, University of Pennsylvania), CD20+ HT1080 cells (transduced
with human CD20 Full-length containing lentivector from G&P Bioscience) and EGFR+
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MDA-MB-468 (ATCC) cells. The binding affinities of syngeneic TRAAbs were
evaluated using 4T1 (ATCC) as well as CT26 and CT26-HER cell lines, provided by
Professor Celeste Simon and Mark Greene, respectively.
Cells were seeded on clear-bottom, black-walled 96-well plates in 100 μL DMEM
or RPMI culture medium (supplemented with 1% P/S and 10% FBS) and kept in a 37°C
cell culture incubator until at least 80% confluency was reached. The cells were fixed by
15 min incubation with 50 μL of 4 % paraformaldehyde per well. After washing twice
with 200 μL PBST buffer (PBS, 0.05% Tween 20, pH-adjusted at 7.2), the cells were
blocked with PBST with 4% normal donkey or goat serum for 1 hour. Serial dilutions of
BiAbs or monoclonal antibodies were added to the target fixed cells and incubated at
room temperature for 1 hr. After washing with PBST, cells were incubated for 1hr with
7.5 ug/mL RhodamineRedX-conjugated donkey anti-human IgG (Jackson Laboratory) or
PE-conjugated goat anti-human or anti-mouse IgG (Invitrogen). Fluorescence readings
were completed with an Infinity M200 (Tecan) or Synergy H1 (BioTek) plate reader.
Binding curves were fit using a saturation (one-site specific) binding model and Kd
values were calculated using GraphPad Prism software (GraphPad Software, La Jolla,
CA, USA).
The binding capabilities of BiAbs, OKT3 and free anti-CD3 scFv were analyzed
using CD3+ human T cells. EZ-Link Sulfo-NHS-LC-Biotin (ThermoFisher) was used for
labelling the antibodies. Serial dilutions of cells were incubated in FACS buffer (PBS,
2% FBS) for 1 h at 4°C. The cells were washed once with FACS buffer, resuspended to
1x106 cells/mL, and incubated with SA-APC (BioLegend) 30 mins at 4°C. After
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incubation with SA-APC, the cells were washed twice with FACS buffer and
resuspended in 200ul of FACS buffer. The fluorescence intensity of the stained cells was
analyzed by flow cytometry.

2.6.5 Human T cells expansion
Healthy human T cells were obtained from the Human Immunology Core
(University of Pennsylvania) and expanded as previously described161. Briefly, equal
amounts of CD4+ and CD8+ T cells were seeded and stimulated with anti-CD3/CD28
activator Dynabeads (Gibco) in a 1:1 ratio. Recombinant human IL2 (Gibco) was added
at 50 IU/mL on the following day and maintained at this concentration 10 days post
seeding. The Dynabeads were magnetically removed 7 days post seeding. Cell density
was maintained at 0.5-1 M/mL throughout the 14-day culture and cell size distribution
was tracked every other day to confirm activation and return to resting state. The final
composition of CD4+ versus CD8+ T cells was checked at the end of the protocol and
confirmed to be around ~60% CD8+ and ~40% CD4+. Following expansion, the
expanded cells were frozen down using a 1:1 mixture of X-VIVO media (Lonza) and
10% DMSO FBS in 50 M/mL aliquots. The cells were thawed in DMEM cell culture
media 24 h before using at a density of 5 M/mL.

2.6.6 Cytokine Secretion Assay
A 96-well plate was coated with 10 nM OKT3, BiAbs or PBS buffer as a negative
control overnight at 4°C. Twenty-four hours later, the wells were washed with PBS and T
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cells (1x106 cells/well) were added for overnight incubation at 37°C. Following the
overnight incubation, the plate was centrifuged at 800xg for 8 minutes. The supernatant
was collected carefully without disturbing the cell pellet. The released interferon-gamma
in the supernatant was quantified using a commercial interferon-gamma ELISA kit
(BioLegend).

2.6.7 T cell-mediated tumor cytolysis assays
For adherent EGFR+, CD20+, and HER2+ target cells, in vitro T cell-mediated
tumor cytolysis assays were performed with the corresponding target cancer cells in the
presence of T cells either at a constant 10:1 effector-to-target (E:T) ratio with varying
treatment concentrations or at constant treatment concentration and varying increasing
E:T ratios, as indicated. Tumor cell viability was tracked using an xCelligence Real-Time
Cell Analysis (ACEA Biosciences).
For suspension Nalm-6 cells, a constant 5:1 E:T ratio was maintained. Viability of
Nalm-6 cells that were genetically engineered to express click beetle luciferase (kindly
provided by Dr. Michael Milone, University of Pennsylvania) was tracked via luciferase
bioluminescence. At each timepoint, 50 µl room temperature Steady-Glo luciferin
substrate (Promega) was thoroughly mixed with 50 µl suspended cells. Bioluminescence
was read using the Synergy H1 plate reader (Biotek). A CD19-CD3 BiAb positive control
was produced using MAB1794 (EMD Millipore) and included for comparison.
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Cytolysis curves were fit using a variable slope dose-response stimulation model
and EC50 values were calculated using GraphPad Prism software (GraphPad Software,
La Jolla, CA, USA).

2.6.8 Endogenous antibodies collection and binding characterization
All animal studies were conducted with approval by the University of
Pennsylvania Institutional Animal Care and Use Committee, in accordance with
AAALAC guidelines and accreditation. Mice were fed standard chow ad libitum unless
otherwise noted. Autoantibodies were raised against either human EGFR+ MDA-MB468 breast cancer cells or human CD19+ Nalm-6 B cell leukemia cells, engineered to
express luciferase, by subjecting 6-10 weeks-old C57BL/6 mice (Charles River
Laboratories, Wilmington, MA) to two weeks of biweekly i.p. injections with 2x106 cells,
followed by two weeks off. This 28-day cycle was repeated twice before collecting the
entire blood volume. The EGFR+ MDA-MB-468 cells were treated with mitomycin C
(40 ug/mL) before injecting the mice. In the Nalm-6 study, blood samples were also
collected after the second and fourth week.
Syngeneic autoantibodies were collected from the sera of BALB/c mice 14-17
days after injecting 1x106 cells subcutaneously. Cells were separated from serum by 15
min high-speed centrifugation, and the antibodies were captured using recombinant
Protein G agarose resin (Invitrogen).
The binding affinity of autoantibodies collected from the sera of Nalm-6 exposed
mice was assessed against live Nalm-6 cells. First, 1x105 Nalm-6 cells were incubated in
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10% normal goat serum, washed in flow buffer (filtered PBS, 1% BSA, 1mM EDTA),
and further blocked using human FcR blocking solution (Miltenyi Biotec).
Autoantibodies from Nalm-6-exposed and healthy mice were incubated 30 min at room
temperature. After washing, a 30 min incubation at room temperature with 1:200
fluorescent secondary anti-mouse antibody (Invitrogen) was used to detect bound
primary. Flow cytometry was performed with a BD Accuri C6.

2.6.9 Nalm-6 in vivo studies in NSG mice
TRAAbs preparation
pAbBD-anti-CD3 nanobodies and control proteins (pAbBD alone and the
nanobody alone) were treated to remove endotoxin using 1% Triton-X-114 phase
separation162. Following photo-crosslinking to the isolated autoantibodies, TRAAbs were
mixed with mouse polyclonal IgGs (BioXCell) to obtain 1 g of background, wildtype
antibodies per mouse. These mixtures were dialyzed in sterile PBS using 100 MCWO
cellulose membrane (Spectrum Labs) and concentrated using polymeric absorbent
Spectra/Gel (Spectrum Labs).
Tumor model and treatment strategy
Male and female NSG mice, aged approximately 6–10 weeks, were obtained from
Stem Cell Xenograft Core, University of Pennsylvania. 5x105 Nalm-6 cells and 1x107
human T cells were injected i.p. along with one third of the treatment. The remaining two
thirds were evenly administered i.p. two and four days later. The total dose was 0.5 mg
TRAAb/kg. For Supplementary Figure 8, 1x106 Nalm-6 cells were injected i.v. 4 days
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prior to treatment. On the first day of treatment, all 5x106 human T cells were injected i.v.
Treatment here was injected i.v. at 2.5 mg/kg, distributed across 5 consecutive days. A
second infusion of 5x106 T cells was also administered on the third day of treatment.
Tumor growth was tracked biweekly using bioluminescent imaging with either
the IVIS Ilumina or Spectrum system (Perkin Elmer). 150 µl of D-luciferin substrate
(Caliper Life Sciences) dissolved at 15 mg/mL in sterile DPBS was injected i.p. 10
minutes prior to imaging. Body weight was recorded weekly. Mice were sacrificed when
bioluminescence total flux reached >1x1010 p/s or earlier if disease symptoms became
apparent, including any combination of hunching, swelling, skin color changes, and
slower behavior. Statistical analysis was performed on day 28 using unpaired t-tests, and
p values less than 0.05 were considered significant. The averages and standard deviations
shown on the bioluminescent summarized graph correspond to 6 or 7 mice used per
group.

2.6.10 Mouse T cell extraction for syngeneic in vitro cytolysis
The fresh spleen was collected from a healthy BALB/c mouse for each
experiment, followed by mechanical digestion in sterile PBS supplemented with 2% FBS.
A single-cell suspension was prepared using a 70 µm strainer, centrifuged 10 min at 300
x g and resuspended at 1x108 cells/mL. A magnetic negative selection kit was then used
to purify out T cells (StemCell). Purified T cells were incubated in RPMI (10% FBS, 1%
P/S) at 1x106 cells/m/L overnight before using in cytolysis experiment.
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2.6.11 T-cell mediated in vitro syngeneic TRAAb cytolysis
These studies were performed following similar steps as the BiAb studies, except
for the following differences. CT26 and 4T1 tumor cells were seeded at 3,000 cells per
well in 100 µl and incubated 30 min – 1 h prior to the addition of 25,000 murine T cells
in 50 µl and 50 µl of treatments diluted in sterile PBS. TRAAbs and controls were
dialyzed in sterile PBS and concentrated using 100 MWCO spin filters (Millipore).
TRAAbs and controls were photo-crosslinked with a pAbBD fusion that included two
copies of the anti-CD3 nanobody. An anti-mouse EGFR antibody conjugated with
pAbBD-CD3-CD3 was used as a positive control in the CT26 model (R&D Systems).
BALB/C WT control IgG purified from sera was purchased from Innovative Research.

2.6.12 Tissue binding studies using solid syngeneic tumor models
BALB/c mice were injected with 1x106 cells subcutaneously. After 14-17 days,
mice were sacrificed and the tumor, liver, spleen, kidney, heart, and lungs were collected.
Tissues were fixed in 10% neutral buffered formalin at least 48hrs at 4°C, followed by
paraffin embedding and sectioning 10 µm thick tissues. Fluorescent staining protocols
followed those previously reported by Rich et al162. Briefly, paraffined sections were
treated with xylene, 1:1 mixture of xylene and ethanol, 100% ethanol, 95% ethanol, 70%
ethanol, 50% ethanol 5 min and washed twice 10 min in DI water. Endogenous
peroxidase activity was blocked using stabilized hydrogen peroxide. Blocking was done
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using a Streptavidin/Biotin kit (Vector Labs), followed by 100% horse serum for 1 hr.
CT26 tissues were stained with and without endogenous circulating antibodies as primary
antibodies at a concentration of 300 nM, diluted in M.O.M. protein concentrate (Vector
Labs). For CT26-HER positive control, mouse anti-human HER2 (Prestige Antibodies)
was used 1:100 diluted in horse serum. Primaries were incubated 2hrs. No primary was
used in 4T1 studies. Biotinylated anti-mouse secondary (Vector Labs) was diluted 1:200
in horse serum and incubated 10 min. Biotinylated equine Fab isotype control (Novus
Biologicals) was used 1:150 to normalize for technical background in each tissue type.
Fluorescent signal was developed using streptavidin-HRP and an Alexa 488 tyramide
SuperBoost kit (Invitrogen). Streptavidin-HRP incubation was optimized to 30 min, and
the HRP reaction time was optimized to 5 minutes. All staining steps were done at room
temperature. Sections were washed twice for 2 min with PBS between all steps, unless
otherwise noted on kits. Stained tissues were mounted using ProLong Diamond antifade
(Invitrogen).
Images were acquired using an Olympus IX81 inverted fluorescent microscope
and a 4X dry objective. For each tissue section stained, 2 or 3 images were obtained and
averaged. The images were equalized and normalized against the corresponding tissue
signal with non-targeted secondary binding using ImageJ. Statistical analysis was
performed using unpaired t-tests between the tumor versus each other tissue type. All
graphs show the mean and standard deviation of 3 to 5 mice.
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CHAPTER 3: SUMMARY AND FUTURE DIRECTIONS

3.1 SUMMARY OF WORK COMPLETED

3.1.1 Functional T cell redirecting bispecific antibodies (BiaBs) made using FDAapproved monoclonal antibodies (mAbs)
We have shown that T cell recruiting bispecific antibodies produced via pAbBD
crosslinking retain parental binding affinity after photo-crosslinking. We have also shown
that the resulting bispecific antibodies are functional in vitro against three different
human cell lines (EGFR+, HER+ and CD20+). The cytolysis kinetics follow as expected,
as do varying effector-to-target (E:T) ratios. The modification reaction is able to
transform nearly all IgGs (except mouse IgG1) with nearly 100% efficiency consistently.
This allows our method to be applied to a broad variety of IgGs without further
optimization. Importantly, multiple IgGs can easily be tested in parallel and compared
against each other.
This first part showed that bispecific antibody formation using pAbBD yields
functional therapeutics that bind as their parental units from which they are derived from
and can induce an anti-tumor effect in vitro.

3.1.2 T cell redirecting autoantibodies (TRAAbs) made using endogenous,
circulating antibodies yield in vitro cytolysis and in vivo tumor suppression and
extended survival
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Next, we showed that the studied method can also be used to transform
endogenous, circulating antibodies into T cell redirecting autoantibodies (TRAAbs).
Here, we used the human lymphoma cell line Nalm-6 to “vaccinate” immunocompetent
mice. We use the term “vaccinate” loosely since this tumor model does not propagate in
immunocompetent mice. The TRAAbs produced using pAbBD photo-crosslinking were
found to be functional in vitro, as observed via dose-dependent cytolysis well as the
expected saturation kinetics. In vivo, tumor regression was also observed, and the
survival of mice treated with TRAAbs was significantly extended and found to be 100%
60 days post treatment initiation.
This part of the thesis showed that in addition to creating functional bispecific
antibodies using FDA-approved IgGs, we can also produce T cell redirecting
autoantibodies (TRAAbs) using IgGs extracted from the serum. TRAAbs function as
expected both in vitro and in vivo.

3.1.3 Antibodies extracted from the sera of syngeneic tumor models induce in vitro
cytolysis and bind tumor tissue preferentially over healthy tissues
We were interested in investigating whether the circulating, endogenous
antibodies of mice bearing syngeneic tumors could also bind and kill tumor cells in a
dose-dependent manner. First, we established three different syngeneic Balb/c models of
colorectal (CT26), renal (RENCA), and triple negative breast cancer (4T1), the latter
having no previously validated clinical targets. The extracted sera IgG were found to bind
tumor cells dose-dependently, while the IgG of healthy Balb/c mice did not. A clear
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therapeutic window was observed in regards to tumor-binding. We then moved on to
testing whether TRAAbs created with the IgGs of two of these models also induced in
vitro cytolysis as previously observed with the FDA-approved IgGs and the Nalm-6
proof-of-concept. The expected dose-dependent cytolysis and kinetics was also observed
here using the CT26 and 4T1 models.
Lastly, we wanted to resolve the autoantibody ability of binding to tumor versus
healthy tissue. Here, we established CT26 and 4T1 in Balb/c mice as well as NSG
immunodeficient mice. In both models we observed a therapeutic window between
binding on tumor versus healthy tissue. In these studies, we stained for mouse IgG on
tumor, heart, lungs, liver, kidney and spleen using the extracted autoantibodies as primary
antibody and an anti-mouse IgG secondary for the CT26 model. In the 4T1 model, the
difference in signal in the tumor versus the other tissues was similar regardless of
whether primary antibody was used or not, indicating prior binding of circulating IgGs at
the time of tissue collection. We normalized the observed signal against a non-targeted
isotype control secondary antibody (equine Fab). As a positive control, we used the cell
line CT26-HER which overexpressed human HER2/neu and Herceptin as the primary
antibody in the staining protocol. To quantify background signal due to the tissue itself
(i.e. not due to pre-bound IgG or due to the secondary or other steps in the protocol) we
also stained the NSG tissues and found no therapeutic window between tumor and
healthy tissue.
In summary, this last thesis aim collected further evidence that related to the
clinical application of TRAAbs. In particular, we resolved whether the tumor-binding and
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anti-tumor effect holds true in syngeneic models, where the immune response is not
primarily xeno-specific. We also resolved a therapeutic window between tumor targeting
versus targeting of healthy major organs.

3.2 FUTURE WORK
The following sections describe multiple ways in which this thesis project could
be further developed to improve the technology and further advance its clinical
application.

3.2.1 Technology development:
Adapting the bispecific formation technology to remove domain of bacterial origin or
reduce safety and efficacy limitations
One of the current limitations for clinical adoption of bispecific antibodies
produced using pAbBD photo-crosslinking is the bacterial origin of the small adaptor
protein domain. The concern here is whether an immune reaction will be elicited against
bacterial motifs, potentially creating a safety risk or rapid inducing clearance of the
therapeutic.
First, our lab has been working on an alternative method to attach proteins, drugs,
or combinations of these onto the C-term of antibodies using Sortase-mediated ligation.
Here, an adaptor protein that conditionally binds IgGs at the Fc regions depending on the
presence of Calcium is fused with the enzyme Sortase. Once the enzyme is in close
proximity to the C-terminal and excess LPETG is available (on its own or conjugated
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with a drug or peptide), isopeptide ligation occurs at a small number of lysine residues
found near the C-term of the Fc region163. Once the reaction is completed, Calcium is
removed to reverse the localization of the pG-Sortase complex, which is then separated
by size exclusion (dialysis, HPLC, spin filter etc). The final product is labelled without
including the bacterial domain.
In previously published work ADCs were formed, however it is conceivable that
instead of using LPETG-drug, we could replace it with LPETG-protein as long as the
minimum concentration for the Sortase-mediated isopeptide reaction is feasible. To
create T cell recruiting autoantibodies, we would need to test whether LPETG-anti-CD3nanobody could be used with this method. In addition to the removal of the bacterial
adaptor protein (pAbBD or protein G), one main advantage of this method is that the Fc
regions are more accessible for recycling, which would restore the bispecific
pharmacokinetics to what’s observed with other Fc-accessible formats.
Derive adaptor protein off human IgG-binding domains to replace current pAbBD
Several human IgG-binding proteins exist naturally and have been studied in
detail to determine their affinity and specificity156,157. The work needed to replace the
currently pAbBD with a domain of human origin would be similar to the article published
by Hui et al163. Briefly, the minimum required domain would need to be determined, and
the position for BPA incorporation would need to be optimized. The downside to the
strategy versus the first one presented by Yu et al is that the Fc regions would be less
accessible in this format, and that an additional non-therapeutic protein would still be part
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of the final construct. While the previously presented method is not entirely traceless, it
still reduces the size of conjugation product significantly.
Scaling up photo-crosslinking reaction for higher volumes
The volumes utilized in these studies were at most in the order of a few milliliters.
In order to move onto potential clinical tests, presumably larger volumes would be
needed. Different sample holders could be developed and tried to increase the surface
area to volume ratio, while maintaining our current light intensity and exposure time.
Optimize IgG extraction from patient sera and photo-crosslinking efficiency
Our current IgG extraction yield from human patients ranges 1-2 mg per mL of
blood, while the concentration of circulating IgG is known to be closer to 10 mg/mL
blood. The IgG extraction protocol can be further optimized in multiple ways. First, the
protein G agarose resin ratio to volume of serum can be increased. Second, the buffers
and pH of the incubation step, as well as the elution step, could be varied by either
increasing the salt concentration and/or utilizing different salts.

3.2.2 Physiological relevance:
Resolve the temporal relationship between cancer clinical stage and humoral response
One of the most important factors that would need to be elucidated for clinical
application is the humoral response in cancer patients. The fundamental question here is:
if we want to use TRAAbs in human, can we do it at any time or only at some times? In
the Nalm-6 model we’ve shown that TRAAbs produced using autoantibodies collected
after 8 weeks of exposure to the tumor cells versus 4 and 2 weeks provides better tumor
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cytolysis in vitro. For a given type of cancer, we would need to establish the tumorbinding specificity and affinity as a function of time, which in patients would be related
to the clinical staging.
For example, we could investigate whether the humoral response is well-defined
as a function of time for a spontaneous, syngeneic murine model. We would need to
develop an antibody binding assay, similar to the one used in this thesis but using biopsy
samples instead of cell lines. We could use fluorescent staining and flow to quantify the
signal. If we find that TRAAbs are not function at specific times (presumably if the
immune system hasn’t had sufficient exposure or, at later stages, if the immune system is
no longer detecting anything- i.e. it’s become tolerant of tumor antigens), the same
antibody binding assay could be used to check matching serum and biopsy samples. This
would mean that not all patients would be eligible for this type of treatment.
Some work was already done to establish a flow-based assay to quantify antibody
binding using an anti-CD20 antibody (BioXCell) as positive control against a murine
lymphoma model (A20 cell line). The difficulty with multiple secondary antibodies was
low signal to noise ratio, while labelling with pAbBD-fluorophores (Alexa 647 for
example) yielded in excessive background signal.
Assess tumor-binding and in vitro cytolysis of patient TRAAbs
The binding assays would follow similar methods as described for spontaneous
murine models. In addition to tumor-binding, it would be interesting to check whether are
functional in vitro. The difficulty here is maintaining the tumor cells obtained via biopsy
alive long enough to allow detection of in vitro cytolysis. Some preliminary work using
125

canine biopsy samples indicate that the tumor cells obtained via biopsy stay alive at least
72hrs. This was checked by counting the cells and assessing cell morphology under the
microscope throughout three days. For cytolysis quantification, a more sensitive methods
would be more appropriate. For example, we could use Calcein-AM and propidium
iodide to track live and dead cells, respectively. alternatively, we could also try
CellTracker or CellTracer dyes.
Quantify percent of tumor-binding IgGs and characterize possible antigens
Another aspect of the circulating, endogenous antibodies that has yet to be
elucidated is the percent of the total IgGs that is tumor-binding. This was attempted using
fixed EGFR+ cells and cetuximab as a positive control. A known amount of IgG was
added, allowed to bind, and then the supernatant was removed. The concentration of
cetuximab detected before and after binding was the same, even though the expected
dose-dependent saturation binding curve was observed. This means that either too small
of a fraction bound on the cells or that our detection method is not sufficiently sensitive.
An alternative strategy is needed here.
Related to the further characterization of endogenous, circulating antibodies are
the potential target antigens. One of the main advantages of utilizing this type of
antibodies as the targeting moiety in a T cell redirecting bispecific is that we do not need
prior knowledge of the tumor antigens. However, it would still be interesting to figure out
what they are identifying that we have not been able to exploit yet. Several methods have
been used previously for this purpose. For example, serological identification of antigens
by recombinant expression cloning (SEREX) use protein microarrays made of pre126

validated proteins to screen for potential specificities of a pool of antibodies. The
downside to this technique is that it is biased towards previous knowledge of antigens and
new antigens would not be identified. An unbiased technique would require proteomics
to elucidate the amino acid sequences of a population of antibodies and a prediction
algorithm to identify potential targets.
Develop method to separate tumor-binding IgGs versus background IgGs
Regardless of our ability to isolate the antigens being targeted by autoantibodies,
this personalized strategy for T cell redirecting autoantibodies would benefit from
distinguishing between tumor-binding versus non-tumor binding IgGs. Presumably, we
have shown that the non-tumor binding IgGs in a pool of IgGs do not necessarily target
healthy tissues, but it would still be beneficial to have control over the final product in
regards to clinical development.
One way this could be done is by immobilizing tumor proteins (extracted from a
biopsy for example) on a solid phase such as agarose and using this as a capture phase,
allowing non-tumor binding IgGs to flow through. This strategy would capture IgGs
targeting intracellular antigens, but whether this is detrimental or beneficial is not clear.
One argument for which this would be good is that as tumor lysis beings to occur,
intracellular antigens would be released, allowing more IgGs to recognize the site of
tumor clearance where treatment is needed. Either way, a sorting strategy utilizing whole
tumor cells seems far less feasible, and would suffer from a different downside in which
if would likely use fixed as opposed to live cells.
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3.2.3 Pharmacokinetics:
One of the most natural next steps in this project is to test whether TRAAbs
function in syngeneic models in vivo. Ideally, for these studies we would transition to
using anti-mouse CD3 fragment as the current ones are anti-human, although we did
observe cytolytic function in vitro. These in vivo studies would help us answer multiple
questions.
First, we would be able to characterize the pharmacokinetics of TRAAbs in a
fully immunocompetent mouse. The impact of crosslinking onto the Fc region of the
autoantibodies is not fully understood yet. We could investigate whether FcRn recycling
is disrupted and quantify the impact on half-life compared to other bispecific formats.
Second, we would like to understand the full immune response in a competent mouse.
The in vivo studies done to date exclusively used NSG immunodeficient mice which we
administered human T cells to. It is possible that we would observe a different response
once the full immune system is present and the different branches can interact with each
other.

3.2.4 Trispecific antibodies and autoantibodies
A second generation of the studied technology would involve the simultaneous
recruitment of either two cellular components or the recruitment and simultaneous
activation of any one cellular component. For example, T cells and NK cells could be
recruited at once or T cells could be recruited and primed for activation by targeting both
CD3 and CD28 at the same time. For either of these strategies, a trispecific antibody
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would be needed. We have the unique advantage of being able to control the labeling
extent (2:1 or 1:1) with the pAbBD photo-crosslinking method, and we could exploit this
to produce otherwise technically challenging constructs. Additionally, we could combine
therapeutic strategies such as recruiting NK cells via CD47 and disrupting T cell
suppression via anti-CTLA-4. As discussed in previous sections in this thesis, synergistic
effects can be achieved when both of these mechanisms of action are co-localized164.
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